Integumentary system disorder
MONDO:0002051A disease involving the integumental system.
Also known as: disease of integumental system, disease or disorder of integumental system, disorder of integumental system, integumental system disease, integumental system disease or disorder, integumentary disease, disorder of integument
4317 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
Showing the 400 most recently updated of 1518 trials in this tab.
-
Lab-Grown skin could transform burn healing
⭐️ CURE ⭐️ Recruiting nowThis trial tests an engineered skin graft called denovoSkin™, made from a patient's own skin cells, for treating deep burns. It aims to see if this graft can close wounds and reduce scarring better than the standard split-thickness skin graft. The study includes adults and adoles…
Phase: PHASE3 • Sponsor: CUTISS AG • Aim: ⭐️ CURE ⭐️
Last updated Aug 12, 2026 00:00 UTC
-
Can shingrix shield HIV patients from shingles?
⭐️ VACCINE ⭐️ Recruiting nowThis study tests the Shingrix vaccine in people with HIV and healthy volunteers to see how well it boosts immunity against shingles. Participants receive two shots two months apart and are followed for a year. The goal is to understand if the vaccine works safely in those with di…
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 15, 2026 00:00 UTC
-
New chickenpox vaccine for toddlers shows promise in safety trial
⭐️ VACCINE ⭐️ Recruiting nowThis study tests a new chickenpox vaccine in 750 healthy children aged 12-15 months. Researchers will compare its safety to the existing Varivax vaccine. The goal is to see if the new vaccine causes similar side effects like injection site pain, fever, or rash.
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 13:00 UTC
-
New chickenpox vaccine shows promise in toddler trial
⭐️ VACCINE ⭐️ Recruiting nowThis study tests a new chickenpox vaccine in healthy children aged 12 to 15 months who have never had chickenpox or the vaccine. Researchers want to see if the new vaccine works as well as the approved Varivax vaccine and if different batches of the new vaccine produce consistent…
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 13:00 UTC
-
New hope for advanced cancers? pfizer launches early trial of PF-08046033
Disease control Recruiting nowThis early-stage study tests a new medicine called PF-08046033 in adults with advanced lung, esophageal, or skin cancers that have spread or can't be removed. The main goal is to check safety and find the right dose. Researchers will also look for early signs that the drug may he…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 18, 2026 03:00 UTC
-
Engineered immune cells take on rare muscle disorders
Disease control Recruiting nowThis Phase 2 trial tests a personalized cell therapy called Descartes-08 for people with dermatomyositis or antisynthetase syndrome, two rare autoimmune diseases that cause muscle weakness and inflammation. The therapy uses a patient's own immune cells, modified to target and red…
Phase: PHASE2 • Sponsor: Cartesian Therapeutics • Aim: Disease control
Last updated Aug 18, 2026 03:00 UTC
-
Can a simple patch stop diabetes device skin woes?
Disease control Recruiting nowThis trial tests whether a silicone-based or a hydrocolloid patch placed under insulin pumps or glucose monitors can prevent contact dermatitis from coming back in children aged 2-18. Participants will use different patches and attend visits for skin exams, ultrasounds, and quest…
Phase: NA • Sponsor: Steno Diabetes Center Copenhagen • Aim: Disease control
Last updated Aug 18, 2026 03:00 UTC
-
Could existing cancer drugs tackle rare tumors? new trial aims to find out
Disease control Recruiting nowThis trial tests whether two approved drugs, dabrafenib and trametinib, can treat rare cancers that have a specific genetic change called BRAF V600. These drugs are already used for melanoma and lung cancer, but researchers want to see if they help people with other cancer types.…
Phase: PHASE2, PHASE3 • Sponsor: Cancer Research UK • Aim: Disease control
Last updated Aug 18, 2026 03:00 UTC
-
Fish oil capsules could ease rare muscle disease
Disease control Recruiting nowThis study tests whether omega-3 fatty acid supplements from fish oil, combined with a healthy diet, can reduce disease activity in adults with dermatomyositis, a rare autoimmune disease causing muscle weakness and skin rashes. About 300 participants will take either fish oil cap…
Phase: PHASE2 • Sponsor: National Institute of Environmental Health Sciences (NIEHS) • Aim: Disease control
Last updated Aug 18, 2026 03:00 UTC
-
Could CAR t cells tame scleroderma? new trial launches
Disease control Recruiting nowThis early-stage study tests a new treatment called CABA-201 for people with systemic sclerosis (scleroderma), a disease that causes hardening of the skin and can damage organs. The treatment uses a patient's own immune cells, modified to target and destroy faulty B cells that dr…
Phase: PHASE2, PHASE3 • Sponsor: Cabaletta Bio • Aim: Disease control
Last updated Aug 18, 2026 03:00 UTC
-
New liquid drug offers hope for kids with severe eczema
Disease control Recruiting nowThis 24-month study tests the long-term safety and effectiveness of abrocitinib, a liquid oral medication, in children aged 2 and older with moderate-to-severe atopic dermatitis (eczema). About 500 participants will receive the drug, with or without topical creams. The goal is to…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 18, 2026 03:00 UTC
-
New shot could help eczema sufferers who Don't respond to steroids
Disease control Recruiting nowThis Phase 3 study tests whether lebrikizumab, an injectable drug, can safely and effectively treat nummular eczema in adults who haven't gotten enough relief from topical steroids or can't use them. About 270 participants will receive either lebrikizumab or a placebo injection. …
Phase: PHASE3 • Sponsor: Almirall, S.A. • Aim: Disease control
Last updated Aug 18, 2026 03:00 UTC
-
New eczema drug shows promise for kids in Late-Stage trial
Disease control Recruiting nowThis study tests whether abrocitinib, a liquid medicine, can improve moderate-to-severe eczema in children aged 6 to 12. About 150 kids will be randomly assigned to receive either the drug or a placebo for 16 weeks. The goal is to see if the medicine clears the skin and reduces i…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 18, 2026 03:00 UTC
-
Could a shot replace the knife for skin cancer?
Disease control Recruiting nowThis phase 3 trial tests whether injecting the drug cemiplimab directly into early-stage skin cancer tumors can work as well as surgery. About 369 people with small tumors on the head, neck, hand, or shin will be randomly assigned to get either the injections or standard surgery.…
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Aug 18, 2026 03:00 UTC
-
New hope for stubborn eczema? abrocitinib tested after biologics fail
Disease control Recruiting nowThis study is tracking 150 adults and teens with moderate-to-severe eczema who have already tried up to two biologic drugs without success. Researchers want to see how well the oral medication abrocitinib (Cibinqo) works in real-world settings. The main goals are to measure impro…
Sponsor: Pfizer • Aim: Disease control
Last updated Aug 18, 2026 03:00 UTC
-
Could a common arthritis drug tame rare immune disease symptoms?
Disease control Recruiting nowThis early study tests baricitinib, a drug already approved for other immune conditions, in 20 people with Job syndrome who also have lupus-like disease or eczema. Participants take the pill daily for 6 months. The main goal is to see if it is safe and tolerable, while also check…
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Aug 18, 2026 03:00 UTC
-
Can a lighter chemo combo spare older breast cancer patients?
Disease control Recruiting nowThis study asks whether a dose-dense chemotherapy combination called CMF (cyclophosphamide, methotrexate, and fluorouracil) can be a practical alternative to the standard AC regimen (doxorubicin and cyclophosphamide) for people aged 70 and older with early-stage breast cancer. Th…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 18, 2026 03:00 UTC
-
Supercharged immune cells take on melanoma in new combo therapy trial
Disease control Recruiting nowThis study tests whether adding the drug pembrolizumab to a treatment that uses a patient's own immune cells (called TIL therapy) can shrink tumors in people with advanced melanoma. About 53 adults aged 18 to 72 who have already tried at least one other treatment will take part. …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New pill aims to boost immune attack on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing an experimental oral drug called GIM-531, alone or with an immunotherapy (anti-PD-1), in 117 adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe, tolerable, and can help th…
Phase: PHASE1, PHASE2 • Sponsor: Georgiamune Inc • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Genetic test may spare thousands of women from unnecessary radiation
Disease control Recruiting nowThis study looks at whether women over 45 with a low-risk type of early breast cancer (DCIS) can avoid radiation after breast-conserving surgery. A genetic test helps identify those with a very low chance of the cancer coming back. The goal is to see if skipping radiation is safe…
Sponsor: Ontario Clinical Oncology Group (OCOG) • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Psoriasis drug may be safe for patients with fatty liver
Disease control Recruiting nowThis study looks at how long adults with plaque psoriasis and a common liver condition called MASLD (fatty liver disease) continue taking the drug secukinumab. Researchers will review medical records from several Spanish hospitals to track treatment duration and changes in liver …
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New drug shows promise for severe eczema in toddlers
Disease control Recruiting nowThis study tests a drug called nemolizumab in toddlers aged 6 to 23 months with moderate-to-severe atopic dermatitis (eczema) that hasn't improved with creams or ointments. The goal is to see how the drug moves through the body, if it is safe, and if it helps control the conditio…
Phase: PHASE2 • Sponsor: Galderma R&D • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a new pill bring back skin color in vitiligo?
Disease control Recruiting nowThis study tests a drug called zasocitinib in adults with nonsegmental vitiligo, an autoimmune condition that causes white patches on the skin. About 200 participants will take either the drug or a placebo for up to a year. The main goal is to see if the drug can improve skin col…
Phase: PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New eczema drug shows promise in Mid-Stage trial
Disease control Recruiting nowThis study tests a new medicine called galvokimig in 160 adults with moderate-to-severe atopic dermatitis (eczema). The goal is to see if different doses can reduce skin redness, itching, and rash better than a placebo. Participants will receive injections and be monitored for 16…
Phase: PHASE2 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Could a stem cell transplant tame tough scleroderma?
Disease control Recruiting nowThis study tests a stem cell transplant using the patient's own blood cells to treat severe scleroderma (systemic sclerosis) that hasn't improved with standard drugs. The goal is to see if this high-dose therapy is safe and can stop the disease from getting worse. The trial enrol…
Phase: PHASE2 • Sponsor: Paul Szabolcs • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a diet tame chronic hives in teens?
Disease control Recruiting nowThis trial asks whether adding a Mediterranean diet or a low-histamine diet to standard care can reduce disease activity and improve quality of life in teens aged 12-18 with chronic spontaneous urticaria (CSU), a condition causing persistent hives. Participants are randomly assig…
Phase: NA • Sponsor: Saglik Bilimleri Universitesi • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New pill aims to shrink spleen in bone marrow cancer
Disease control Recruiting nowThis phase 3 trial tests a new drug called flonoltinib maleate in people with intermediate- or high-risk myelofibrosis, a type of bone marrow cancer. The study compares flonoltinib to an existing drug, ruxolitinib, to see if it can reduce spleen size and improve symptoms. About 1…
Phase: PHASE3 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a drug calm severe eczema itch when the rash is mild? a new study investigates
Disease control Recruiting nowThis study looks at teenagers aged 12 to 17 who have severe atopic dermatitis (eczema) with intense itching but only a mild to moderate rash. They are being treated with dupilumab (Dupixent), a standard medication. The goal is to see how well dupilumab controls itching, improves …
Sponsor: Sanofi • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Blood test could spare thousands from unnecessary breast cancer treatment
Disease control Recruiting nowThis study is testing whether a simple blood test that looks for cancer DNA can help doctors decide when to start a targeted therapy (CDK4/6 inhibitor) in people with intermediate-risk HR+ HER2- breast cancer. About 725 participants will have their blood tested every 3 months for…
Phase: NA • Sponsor: Natera, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New STING agonist drug enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial tests the safety of CRD3874-SI, a drug that activates the STING pathway to boost the immune system against cancer. About 81 adults with advanced solid tumors (sarcoma, Merkel cell carcinoma, and others) will receive weekly IV infusions at increasing doses. …
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New hope for myelofibrosis patients who failed standard therapy
Disease control Recruiting nowThis study tests an experimental drug called flonoltinib maleate in about 64 people with a rare bone marrow cancer (myelofibrosis) that is moderate to high risk and has not responded to or stopped responding to standard JAK inhibitor therapy. Participants take a daily pill on an …
Phase: PHASE2 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New gel could ease blistering for skin disorder patients
Disease control Recruiting nowThis study tests a gel called TolaSure on people aged 4 and older with epidermolysis bullosa simplex, a condition that causes fragile skin and blisters. For the first 2 months, some participants get the gel and others get a placebo; then everyone gets the gel for another 2 months…
Phase: PHASE2 • Sponsor: BioMendics, LLC • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New eczema drug TRB-061 enters first human trials
Disease control Recruiting nowThis early-stage trial tests a new drug called TRB-061 in healthy adults and people with moderate-to-severe atopic dermatitis (eczema). The study checks for safety, side effects, and how the drug moves through the body. Participants receive either TRB-061 or a placebo as injectio…
Phase: PHASE1 • Sponsor: TRex Bio, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a reformulated gel plus light therapy better tackle precancerous skin spots?
Disease control Recruiting nowThis trial is testing a reformulated version of a topical drug called Levulan Kerastick, which is applied to actinic keratosis (AK) lesions on the face or forearms. After the drug sits on the skin for a few hours, it is activated by blue light in a process called photodynamic the…
Phase: PHASE1 • Sponsor: Sun Pharmaceutical Industries Limited • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Biomarker-Guided combo aims to outsmart tough cancers
Disease control Recruiting nowThis phase II trial is testing whether the combination of cabozantinib (a targeted therapy) and nivolumab (an immunotherapy) can shrink or stabilize advanced melanoma and head and neck cancers that have stopped responding to prior immunotherapy. Researchers are also checking if t…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Radiation-Free path for young breast cancer patients? trial tests skipping therapy
Disease control Recruiting nowThis trial is testing whether young women under 40 with a very early, low-risk form of breast cancer called ductal carcinoma in situ (DCIS) can safely avoid radiation therapy after having breast-conserving surgery. Instead of radiation, participants will be closely monitored, and…
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a stent heal leg ulcers that Won't close?
Disease control Recruiting nowThis study tests whether placing a stent in a blocked pelvic vein can help heal chronic leg ulcers in people with post-thrombotic syndrome, a complication of deep vein thrombosis. Twenty adults with non-healing venous ulcers will receive the stenting procedure plus standard ulcer…
Phase: NA • Sponsor: Ain Shams University • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Could a higher dose of this pill regrow hair in severe alopecia?
Disease control Recruiting nowThis study tests two daily doses (50 mg and 100 mg) of the medicine ritlecitinib in about 550 people aged 12 and older with severe alopecia areata, a condition causing significant hair loss on the scalp and body. The 50 mg dose is already approved, and researchers want to see if …
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New cream could help kids with 'Butterfly Skin' heal faster
Disease control Recruiting nowThis phase 3 trial tests whether a cream called SD-101 can help close wounds in children with epidermolysis bullosa (EB), a condition that causes fragile, blistering skin. About 80 children aged 1 month to 12 years will apply the cream or a placebo to their whole body for 2 month…
Phase: PHASE3 • Sponsor: Paradigm Therapeutics • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Could some breast cancer patients skip radiation entirely?
Disease control Recruiting nowThis trial is asking whether women with a very early, non-invasive breast condition called ductal carcinoma in situ (DCIS) can safely skip radiation therapy after having breast-conserving surgery. The study focuses on women aged 40 and older with low- or intermediate-risk DCIS th…
Phase: PHASE3 • Sponsor: Fudan University • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New hope for immunocompromised skin cancer patients: amivantamab combo tested
Disease control Recruiting nowThis phase II trial tests whether a combination of amivantamab and hyaluronidase works as well as cetuximab for treating skin squamous cell carcinoma that has come back or spread. The study enrolls 86 immunocompromised participants, including organ transplant recipients. The goal…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a drug duo outsmart a rare skin cancer?
Disease control Recruiting nowThis trial is testing whether combining two drugs, golidocitinib and chidamide, can shrink tumors in people with cutaneous T-cell lymphoma (CTCL), a rare type of cancer that affects the skin. The study includes adults with CTCL that has not improved or has returned after at least…
Phase: PHASE1, PHASE2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New virus therapy takes on advanced cancers in first human trial
Disease control Recruiting nowThis early-phase study tests a new treatment called MQ710, a modified virus injected directly into tumors, alone or with the immunotherapy drug pembrolizumab. It is for people with advanced solid tumors (like skin cancer or head and neck cancer) that have not responded to standar…
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New eczema drug shows promise in Mid-Stage trial
Disease control Recruiting nowThis study tests whether IMG-007 can safely reduce eczema symptoms like itching and redness in adults with moderate-to-severe disease who haven't responded well to topical treatments. About 405 participants will receive either the drug or a placebo, and researchers will measure s…
Phase: PHASE2 • Sponsor: Inmagene LLC • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New oral option may offer relief for hereditary angioedema attacks
Disease control AVAILABLEThis program provides access to an experimental oral medication called deucrictibant for people with hereditary angioedema (HAE) who have no satisfactory alternative treatments for acute attacks. Eligible participants, aged 12 to 75, take the capsule as needed to manage swelling …
Sponsor: Pharvaris Netherlands B.V. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New eczema drug shows promise in Mid-Stage trial
Disease control Recruiting nowThis study tests a new medication called camoteskimab for adults with moderate-to-severe atopic dermatitis (eczema). About 280 participants will receive either the drug or a placebo to see if it reduces skin redness, thickness, and itching over 24 weeks. The goal is to find a saf…
Phase: PHASE2 • Sponsor: Apollo Therapeutics Ltd • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug KUP-101A enters first human tests for advanced skin cancers
Disease control Recruiting nowThis early-stage study tests a new drug called KUP-101A in 21 people with advanced skin cancers (like melanoma or Merkel cell carcinoma) that have not responded to other treatments. The main goals are to find the safest dose and check for side effects. Researchers will also measu…
Phase: PHASE1 • Sponsor: Kupando GmbH • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New pill targets rosacea inflammation at its source
Disease control Recruiting nowThis study tests an oral medication called remibrutinib for adults with moderate-to-severe papulopustular rosacea, a skin condition causing red bumps and pustules on the face. The drug works by blocking a protein involved in inflammation. Researchers will measure whether it reduc…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New cell therapy HN2301 enters human trials for autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a new therapy, HN2301, in 30 adults with lupus, scleroderma, or rheumatoid arthritis. The main goal is to check safety and find the right dose. Researchers will also look for early signs that the treatment helps control the disease by measuring immune…
Phase: PHASE1 • Sponsor: Shenzhen MagicRNA Biotechnology Co., Ltd • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug targets root cause of rare overgrowth syndromes
Disease control Recruiting nowThis Phase 2 study tests an oral drug called RLY-2608 in adults and children with overgrowth conditions (like CLOVES or Klippel-Trenaunay syndrome) caused by PIK3CA gene mutations. The drug is designed to block the faulty protein driving abnormal tissue growth. The trial will enr…
Phase: PHASE2 • Sponsor: Relay Therapeutics, Inc. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a new immune drug outsmart Hard-to-Treat tumors?
Disease control Recruiting nowThis trial tests an experimental drug called STAR0602, which is designed to help the immune system attack cancer cells. It is being studied in people with advanced solid tumors that have not responded to standard treatments. The drug is given alone or combined with chemotherapy, …
Phase: PHASE1, PHASE2 • Sponsor: Marengo Therapeutics, Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a common amino acid outperform chemotherapy cream to restore skin color?
Disease control Recruiting nowThis trial tests whether applying tyrosine or 5-fluorouracil to the skin, combined with a fractional erbium YAG laser, can help restore color in people with focal vitiligo. Vitiligo is an autoimmune condition that causes white patches by destroying pigment-making cells. The study…
Phase: EARLY_PHASE1 • Sponsor: Aswan University • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Fasting during chemo: a new way to boost treatment?
Disease control Recruiting nowThis trial tests whether time-restricted eating (TRE) — a 16:8 fasting schedule — is feasible for patients with HER2-negative breast cancer undergoing neoadjuvant chemotherapy. Participants will follow TRE for 16 weeks while receiving chemo, and researchers will measure how many …
Phase: PHASE2 • Sponsor: Thomas Jefferson University • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New oral drug shows promise for rare sun allergy conditions
Disease control Recruiting nowThis study is for people with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP), rare conditions that cause severe pain and skin reactions to sunlight. The purpose is to check the long-term safety of an oral medication called dersimelagon. About 301 participant…
Phase: PHASE3 • Sponsor: Tanabe Pharma America, Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New hope for skin cancer patients with complex medical histories
Disease control Recruiting nowThis study tests a drug called cosibelimab in 80 people with advanced skin cancer who also have a kidney transplant or a blood cancer. The drug works by helping the immune system attack cancer cells. Researchers will check if the tumors shrink and monitor for side effects.
Phase: PHASE4 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Could a Two-Drug combo reawaken the immune system against resistant cancers?
Disease control Recruiting nowThis trial tests whether combining bexmarilimab with nivolumab can help people whose cancers no longer respond to immunotherapy. It focuses on two cancers: non-small cell lung cancer and melanoma. The study first finds the safest dose of bexmarilimab to give with a fixed dose of …
Phase: PHASE1, PHASE2 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New ointment aims to restore skin color in vitiligo
Disease control Recruiting nowThis Phase 3 trial tests whether an ointment called MH004 can help restore skin color in people with non-segmental vitiligo. The study includes adolescents and adults aged 12 to 75 with facial vitiligo. Participants apply the ointment twice daily for 24 weeks, and researchers mea…
Phase: PHASE3 • Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New pill could clear psoriasis in teens
Disease control Recruiting nowThis study tests a daily pill called deucravacitinib in teenagers aged 12 to 18 with moderate to severe plaque psoriasis. About 366 participants will receive either the drug or a placebo. The main goals are to see if the drug improves skin clearance by at least 75% and reduces ov…
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drug BBD-1 shows promise for painful skin and kidney disease
Disease control Recruiting nowThis study tests a new drug, BBD-1, against standard steroids for IgA vasculitis, a disease that causes purple spots on the skin, joint pain, and can damage the kidneys. The trial will enroll 30 adults with confirmed IgA vasculitis. The goal is to see if BBD-1 can clear skin spot…
Phase: PHASE2 • Sponsor: Qifeng Zhang • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancers in large trial
Disease control Recruiting nowThis phase 2 trial is testing an experimental drug called patritumab deruxtecan (HER3-DXd) in 740 people with advanced solid tumors, including melanoma, lung, breast, and other cancers. The drug is given by IV every three weeks. The main goal is to see if the drug shrinks tumors.…
Phase: PHASE2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Brain training targets impulse control to fight OCD and related disorders
Disease control Recruiting nowThis study tests whether a computerized training program designed to improve response inhibition — the ability to stop an automatic action — can reduce symptoms in people with obsessive-compulsive disorder, trichotillomania (hair-pulling), or skin-picking disorder. Participants a…
Phase: NA • Sponsor: University of Wisconsin, Milwaukee • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New cancer drug MBS8(1V270) enters first human trials
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called MBS8(1V270), given alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 1…
Phase: PHASE1 • Sponsor: MonTa Biosciences ApS • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New skin disease drug enters first human trials
Disease control Recruiting nowThis study tests a new drug called BG-A3004 for the first time in humans. It aims to check the drug's safety and how the body processes it in healthy volunteers and people with immune-related skin diseases. The study is split into two parts: single dose in healthy people and mult…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Gene-Edited cells take on lupus and scleroderma in first human test
Disease control Recruiting nowThis early-stage trial tests a single infusion of CRISPR-edited immune cells (CTX112) from a healthy donor in 80 adults with severe lupus, scleroderma, or myositis that hasn't responded to standard treatments. The goal is to see if the cells are safe and can reduce disease activi…
Phase: PHASE1 • Sponsor: CRISPR Therapeutics • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New pill for chronic hives enters first human tests
Disease control Recruiting nowThis early-stage trial tests a single oral dose of HRS-3095, a new drug for chronic spontaneous urticaria (chronic hives), in 36 healthy adults. The main goal is to check safety and how the drug moves through the body. Results will guide future studies in patients with hives.
Phase: EARLY_PHASE1 • Sponsor: Atridia Pty Ltd. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Botox injections could tame painful skin disease
Disease control Recruiting nowThis study is testing whether Botox injections can reduce inflammation in people with hidradenitis suppurativa (HS), a chronic skin condition that causes painful lumps. Researchers believe that blocking certain nerve signals may calm the immune response. The study will enroll 20 …
Sponsor: University of Massachusetts, Worcester • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New eczema drug ZL-1503 enters first human safety trial
Disease control Recruiting nowThis early-stage trial is testing a new drug called ZL-1503 for safety and how the body processes it. It involves 84 participants: first healthy volunteers, then people with moderate to severe atopic dermatitis (eczema). The study is 'double-blind' and 'placebo-controlled,' meani…
Phase: PHASE1 • Sponsor: Zai Lab (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New cream could ease painful skin condition lichen sclerosus
Disease control Recruiting nowThis study tests a cream called delgocitinib for lichen sclerosus, a skin condition that causes itching, pain, and scarring in the genital area. About 652 adults with mild to severe disease will apply the cream twice daily for up to 52 weeks. Researchers will check if the cream i…
Phase: PHASE3 • Sponsor: LEO Pharma • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New pill for chronic hives tested in everyday clinics
Disease control Recruiting nowThis study follows 470 adults with chronic spontaneous urticaria (hives) who are starting remibrutinib, a new drug. Researchers will track how well it controls symptoms and any side effects over two years in real-world clinics. The goal is to see if remibrutinib works as well out…
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Immune cell therapy takes on autoimmune diseases
Disease control Recruiting nowThis study tests a new treatment called NKX019 for people with autoimmune diseases like systemic sclerosis, rheumatoid arthritis, and vasculitis. NKX019 uses specially engineered immune cells to target and calm overactive B cells that cause the disease. The goal is to see if it i…
Phase: PHASE1, PHASE2 • Sponsor: Nkarta, Inc. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Wart war: vitamin D3 or acyclovir injections – which works better?
Disease control Recruiting nowThis study tests whether injecting acyclovir (an antiviral drug) or vitamin D3 directly into skin warts can clear them. Forty people aged 12 and older with common, plantar, flat, or nail warts will receive injections every two weeks for up to four sessions. The main goal is to se…
Phase: PHASE4 • Sponsor: Riphah International University • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New IV drug hopes to regrow hair in severe alopecia
Disease control Recruiting nowThis study tests a new drug called LY4005130 for adults with severe alopecia areata, a condition causing significant hair loss. About 60 participants will receive either the drug or a placebo intravenously. The goal is to see if the drug can regrow hair and to check for side effe…
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New shot aims to recolor white patches in vitiligo
Disease control Recruiting nowThis study tests an experimental drug called LY4005130 in 60 adults with non-segmental vitiligo, a condition that causes white patches on the skin. Participants receive either the drug or a placebo by IV every few weeks for 24 weeks. The goal is to see if the drug can reduce the …
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New eczema pill shows promise in Mid-Stage trial
Disease control Recruiting nowThis study tests an experimental pill called ENV-294 for adults with moderate-to-severe atopic dermatitis (eczema). About 200 participants will take either one of three doses of ENV-294 or a placebo daily for 12 weeks. Researchers will measure changes in eczema severity, symptoms…
Phase: PHASE2 • Sponsor: Enveda Therapeutics • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Eczema drug afimkibart tested for Long-Term safety in new study
Disease control Recruiting nowThis study looks at the long-term safety and effectiveness of the drug afimkibart for people with atopic dermatitis (eczema) who have already taken it in earlier studies. About 120 adults will be followed to see how well the drug controls their eczema over time and what side effe…
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
HS patients who responded to drug get extended access in new study
Disease control Recruiting nowThis study offers continued treatment with povorcitinib for up to 600 adults with hidradenitis suppurativa who completed a prior trial and saw benefit. The main goal is to track side effects over time, with a secondary focus on reducing skin abscesses, nodules, and tunnels. Parti…
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New hope for teens with painful skin condition: experimental drug povorcitinib under study
Disease control Recruiting nowThis study tests an oral drug called povorcitinib in 40 adolescents aged 12 to 17 with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition causing painful boils and tunnels. Over 54 weeks, researchers will check the drug's safety, how the body processes it,…
Phase: PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New cream could ease painful skin condition
Disease control Recruiting nowThis early-stage trial tests a cream called ruxolitinib on people with hidradenitis suppurativa, a condition causing painful lumps under the skin. The study includes 24 adults and teens and focuses on safety and how much of the drug gets into the body. Participants apply the crea…
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a new pill help the immune system fight cancer?
Disease control Recruiting nowThis trial is testing an investigational drug called ARV-6723, given as a pill, in people with advanced solid tumors. The drug is designed to help the immune system recognize and attack cancer cells. The study will test ARV-6723 alone and in combination with pembrolizumab, an imm…
Phase: PHASE1, PHASE2 • Sponsor: Arvinas Inc. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New drug EVOLVE104 takes on tough cancers in early human trial
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called EVOLVE104 in people with advanced bladder cancer or several types of squamous cell carcinoma (lung, esophagus, skin, and others). The study aims to find a safe dose and see if the drug can shrink tumors. It is for pati…
Phase: PHASE1 • Sponsor: EvolveImmune United, Inc • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New drug aims to halt lung damage in autoimmune patients
Disease control Recruiting nowThis study tests whether the drug nerandomilast can slow lung scarring in people with autoimmune diseases like rheumatoid arthritis or scleroderma. About 400 adults whose lung function hasn't improved with standard treatment will take either nerandomilast or a placebo twice daily…
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Could Once-Daily radiation replace Twice-Daily for breast cancer recurrence?
Disease control Recruiting nowThis study is for women whose breast cancer has come back after initial breast-conserving surgery and whole breast radiation. The standard treatment after repeat surgery is radiation twice a day for 30 sessions. This trial tests whether giving radiation once a day for 15 sessions…
Phase: PHASE2 • Sponsor: Case Comprehensive Cancer Center • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New pill vs. injection: which works better for kids with severe eczema?
Disease control Recruiting nowThis study tests two medicines for children aged 2 to 12 with moderate to severe eczema that isn't controlled by creams. One group gets upadacitinib (a daily pill or liquid), the other gets dupilumab (an injection every 2 or 4 weeks). The goal is to see which better reduces skin …
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Hope for scleroderma: new pill aims to halt disease progression
Disease control Recruiting nowThis Phase 3 trial tests whether the oral drug nerandomilast can slow disease progression in adults with systemic sclerosis (scleroderma). About 448 participants will be randomly assigned to receive either nerandomilast or a placebo twice daily for up to 4 years. Researchers will…
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New drug aims to stop swelling attacks in hereditary angioedema
Disease control Recruiting nowThis phase 3 study tests an intravenous C1 esterase inhibitor (C1-INH) in people with hereditary angioedema (HAE) to treat acute attacks and prevent attacks before medical procedures. About 124 participants, aged 2 and older, will receive either the drug or a placebo. The main go…
Phase: PHASE3 • Sponsor: Octapharma • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New drug INCA036873 enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests an experimental drug called INCA036873 in about 280 adults with advanced solid tumors or certain blood cancers that have worsened after standard treatments. The main goal is to check safety and find the right dose. Participants receive the drug throug…
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Promising drug combo may stop painful flare-ups in rare bone disease
Disease control Recruiting nowThis study looks at whether anti-inflammatory drugs (like anakinra or canakinumab) can reduce painful flare-ups and prevent extra bone growth in people with a rare genetic condition called fibrodysplasia ossificans progressiva (FOP). Eleven people with severe FOP will be tracked …
Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can an mRNA therapy supercharge the immune system against cancer?
Disease control Recruiting nowThis trial is testing an experimental therapy called STX-003, which uses mRNA to produce a protein that may help the immune system fight cancer. It is given intravenously, either alone or with the immunotherapy drug pembrolizumab (Keytruda). The study involves adults with advance…
Phase: PHASE1, PHASE2 • Sponsor: Strand Therapeutics Inc. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a tiny biopsy outsmart skin Cancer's spread?
Disease control Recruiting nowThis trial tests whether removing and examining the sentinel lymph node—the first node a skin cancer might spread to—can catch metastasis earlier than standard monitoring. Half of the 142 participants with high-risk cutaneous squamous cell carcinoma will receive the biopsy plus s…
Phase: NA • Sponsor: Germans Trias i Pujol Hospital • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Stop the pills when symptoms vanish? landmark trial for Kids' infections
Disease control Recruiting nowThis study tests whether children with bacterial infections like urinary tract infections, cellulitis, or pneumonia can safely stop oral antibiotics once their symptoms go away, instead of finishing the entire course. About 200 children aged 1 to 17 who have already received IV a…
Phase: PHASE4 • Sponsor: Murdoch Childrens Research Institute • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New drug could help rare fat disorder patients
Disease control Recruiting nowThis study tests a new drug called mibavademab for people with generalized lipodystrophy, a rare condition where the body lacks fat tissue. The goal is to see if the drug can improve blood sugar, lower blood fats, and reduce liver fat. About 28 children and adults will take part …
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New combo therapy aims to outsmart resistant head and neck cancer
Disease control Recruiting nowThis study tests whether adding cetuximab to standard immunotherapy (pembrolizumab) helps people with advanced head and neck cancer that has stopped responding to platinum chemotherapy live longer. About 158 adults with cancer that has returned or spread will receive either pembr…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a new injection tame hereditary swelling attacks?
Disease control AVAILABLEThis program provides access to an investigational drug called donidalorsen for people with hereditary angioedema (HAE), a genetic condition that causes sudden, painful swelling in various body parts. The drug is given as a monthly or every-other-month injection under the skin. I…
Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Experimental drug plus radiation aims to tackle returning head and neck cancers
Disease control Recruiting nowThis early-phase trial is testing whether a drug called camonsertib, combined with a precise type of radiation, can help control head and neck cancers that have come back or cannot be removed by surgery. About 39 adults with these cancers will receive the drug along with focused …
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New drug trial hopes to thicken skin Disease's fate
Disease control Recruiting nowThis study tests an experimental drug called MTX-474 in 85 people with diffuse cutaneous systemic sclerosis, a condition that causes skin thickening and organ damage. Participants will receive either MTX-474 or a placebo for 24 weeks to see if the drug safely reduces skin thickne…
Phase: PHASE2 • Sponsor: Mediar Therapeutics • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New hope for kids with rare swelling disorder as drug trial begins
Disease control Recruiting nowThis study tests a drug called donidalorsen in 20 children aged 2 to 12 with hereditary angioedema (HAE), a condition that causes sudden, painful swelling. The goal is to see if the drug is safe and how it works in young bodies. Researchers will monitor side effects and measure h…
Phase: PHASE3 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a switch to guselkumab clear stubborn psoriasis?
Disease control Recruiting nowThis study looks at how well guselkumab works for people with moderate to severe psoriasis who switch from ustekinumab (or its biosimilar) in a real-world setting. Researchers will track skin clearance using the PASI score at various time points over a year. The goal is to see if…
Sponsor: Janssen-Cilag Kft. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Psoriasis drug risankizumab under Real-World spotlight for quality of life boost
Disease control Recruiting nowThis study follows 700 adults with moderate-to-severe plaque psoriasis who are already prescribed risankizumab by their doctor. Researchers will track changes in quality of life, including skin symptoms and daily impacts, over up to 2.5 years. The goal is to see how well the drug…
Sponsor: AbbVie • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New psoriasis drug ORKA-001 tested for Long-Term safety
Disease control Recruiting nowThis study is testing the long-term safety and effectiveness of a drug called ORKA-001 for people with moderate-to-severe plaque psoriasis. It is an open-label extension, meaning everyone gets the drug, and it includes 240 adults who already completed a previous trial with ORKA-0…
Phase: PHASE2 • Sponsor: Oruka Therapeutics, Inc. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New drug Rina-S shows promise in battling Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug, Rina-S, in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to see if Rina-S is safe and how well it works against cancers like ovarian, lung, and breast cancer. About 884 participants will receive the dru…
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New foot fungus film shows promise in early trial
Disease control Recruiting nowThis early-stage trial tests a new topical film called ZYG24004 for athlete's foot (tinea pedis). About 64 adults with the infection will apply the film to their feet once or twice. The main goals are to check safety, how the body processes the drug, and whether it can clear the …
Phase: PHASE1 • Sponsor: Sinomune Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Could a simple sugar pill fix faulty telomeres? early trial launches
Disease control Recruiting nowThis early-stage trial is testing whether a combination of two natural substances, deoxycytidine and deoxythymidine, is safe for people with telomere biology disorders. These rare genetic conditions cause premature aging, bone marrow failure, and lung scarring. Up to 36 participa…
Phase: PHASE1 • Sponsor: Suneet Agarwal • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Diet and exercise may tame psoriasis in kids — a trial puts it to the test
Disease control Recruiting nowThis trial tests whether a gluten-free, low-histamine diet — alone or combined with a supervised physical therapy program — can reduce skin severity and inflammation in children aged 6 to 17 with mild to moderate psoriasis. Sixty participants are randomly assigned to usual care, …
Phase: NA • Sponsor: Mahmoud Usama Mahmoud Ahmed • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Could a Two-Drug punch before surgery shrink head & neck tumors?
Disease control Recruiting nowThis study tests whether adding an experimental drug (CDX-1140) to a standard immunotherapy (cemiplimab) before surgery can shrink advanced head and neck cancers more than the immunotherapy alone. About 44 people with stage III-IV head and neck cancer will receive either the comb…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New drug aims to calm severe eczema without steroids
Disease control Recruiting nowThis study tests an experimental drug called rezpegaldesleukin (NKTR-358) for people aged 12 and older with moderate-to-severe atopic dermatitis, a type of eczema. Participants receive either the drug or a placebo as a shot under the skin. The goal is to see if the drug can clear…
Phase: PHASE3 • Sponsor: Nektar Therapeutics • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Could less be more? new study tests lower doses of cancer drug
Disease control Recruiting nowThis study is testing whether giving lower, less frequent doses of the cancer drug atezolizumab can still keep enough drug in the blood to fight cancer. About 30 adults with certain advanced cancers (like lung cancer or melanoma) will start with standard doses, then switch to a l…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New biologic XmAb657 enters first human tests for autoimmune conditions
Disease control Recruiting nowThis early-phase trial is testing a new biologic drug called XmAb657 in 60 people, including healthy volunteers and those with autoimmune diseases like scleroderma, Sjögren's disease, and idiopathic inflammatory myopathies. The main goal is to check safety and how the body handle…
Phase: PHASE1 • Sponsor: Xencor, Inc. • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New drug hopes to heal painful skin ulcers in rare disease
Disease control Recruiting nowThis study tests whether spesolimab, given as an infusion, can help close skin ulcers in adults with pyoderma gangrenosum, a rare inflammatory skin condition. About 90 participants will receive either spesolimab or a placebo, along with corticosteroids. The trial lasts about 1.5 …
Phase: PHASE3 • Sponsor: LEO Pharma • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New hope for rare childhood cancer: drug cocktail aims to shrink tumors and prevent return
Disease control Recruiting nowThis study is for children and young adults (up to age 30) with a rare type of soft tissue cancer called non-rhabdomyosarcoma. It tests whether adding the drugs pazopanib and selinexor to standard chemotherapy can improve outcomes. Participants receive treatment tailored to their…
Phase: PHASE1, PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can a pill reverse severe baldness? major trial underway
Disease control Recruiting nowThis phase 3 trial tests whether upadacitinib (Rinvoq) can help regrow hair in people with severe alopecia areata, an autoimmune condition that causes patchy or total hair loss. About 1500 adults and teens will receive either the drug or a placebo daily for up to 160 weeks. The m…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New shot could tame stubborn hives when pills fail
Disease control Recruiting nowThis study tests an injection called JYB1904 in 180 adults with chronic spontaneous urticaria (hives and itching lasting over 6 weeks) that isn't well controlled by standard antihistamines. Participants receive either the drug or a placebo every 12 weeks for 48 weeks. The main go…
Phase: PHASE3 • Sponsor: Jemincare • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Experimental CAR-T therapy takes on lupus and more
Disease control Recruiting nowThis early-stage study tests a new treatment called RD06-05, a universal CAR-T cell therapy, in up to 84 adults with autoimmune diseases like lupus, vasculitis, and scleroderma. The therapy targets and removes faulty immune cells to help control the disease. The main goal is to c…
Phase: EARLY_PHASE1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New hope for rare sun allergy: bitopertin offered to patients with no options
Disease control AVAILABLEThis expanded access program provides bitopertin (DISC-1459) to patients aged 12 and older with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP) who have no satisfactory treatment options in the US. The goal is to offer access and gather safety information. Pa…
Sponsor: Disc Medicine, Inc • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Could a common diabetes drug boost immunotherapy in Hard-to-Treat cancers?
Disease control Recruiting nowThis early-phase trial is testing whether adding sitagliptin, a diabetes drug, to the immunotherapy pembrolizumab is safe and can help people with advanced kidney cancer or melanoma whose cancer has stopped responding to standard treatment. The study will first find the safest do…
Phase: PHASE1 • Sponsor: Fernando Maciel Barbosa • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Can an ancient herbal mix tame psoriasis flares?
Disease control Recruiting nowThis trial tests whether a traditional Chinese herbal formula called SDD can safely reduce the severity of plaque psoriasis, a common inflammatory skin condition. Adults with mild-to-moderate psoriasis will receive either SDD or a placebo daily for 12 weeks. Researchers will meas…
Phase: PHASE2 • Sponsor: Chinese University of Hong Kong • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Ancient herbal mix put to the test against childhood eczema
Disease control Recruiting nowThis trial tests whether a modified version of the traditional Chinese herbal formula Qing-Ying Decoction can reduce eczema severity in children aged 4 to 17. Participants receive either the herbal granules or a placebo for 12 weeks, followed by 4 weeks of monitoring. Researchers…
Phase: PHASE2, PHASE3 • Sponsor: Chinese University of Hong Kong • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Can a pill beat dandruff? oral antifungal takes on stubborn scalp condition
Disease control Recruiting nowThis trial tests whether oral itraconazole, taken as a pulse therapy over six months, works better than a standard ketoconazole shampoo for moderate to severe scalp seborrheic dermatitis. Eighty participants aged 14 to 70 will be randomly assigned to one of the two treatments. Re…
Phase: EARLY_PHASE1 • Sponsor: Combined Military Hospital (CMH) institute of Medical Sciences Bahawalpur Pakistan • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New drug IDP-001 takes on advanced cancers in early trial
Disease control Recruiting nowThis study tests an experimental drug called IDP-001 in people with advanced or metastatic solid tumors, including certain lung, head and neck, and other cancers. The trial has two phases: first to check safety and find the right dose, then to see if the drug can shrink tumors. A…
Phase: PHASE1, PHASE2 • Sponsor: InduPro, Inc. • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can a common antibiotic beat MRSA in kids? a trial puts TMP-SMX to the test
Disease control Recruiting nowThis trial compares two oral antibiotics—trimethoprim-sulfamethoxazole (TMP-SMX) and clindamycin—to see which works better for children with invasive MRSA infections, such as bone, joint, or deep tissue infections. About 100 children aged 60 days to 18 years will take one of the …
Phase: PHASE4 • Sponsor: Indiana University • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New Pill-and-Immunotherapy combo aims to shrink melanoma before surgery
Disease control Recruiting nowThis phase 2 trial tests whether adding an experimental immune-boosting pill (PRTX007) to standard immunotherapy (pembrolizumab) before surgery can improve outcomes for people with stage III melanoma. About 48 adults with resectable melanoma will take the combination for 9 weeks …
Phase: PHASE2 • Sponsor: Primmune Therapeutics, Inc. • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Microscopic skin scans may reveal how a new eczema drug reshapes the skin
Disease control Recruiting nowThis study tests whether reflectance confocal microscopy (RCM), a noninvasive imaging technique, can detect structural changes in the skin of people with moderate-to-severe atopic dermatitis (eczema) who are treated with nemolizumab. Nemolizumab is an antibody that blocks IL-31, …
Sponsor: Hôpitaux Drôme Nord • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Can a sticky film shield breast cancer patients from radiation burns in tropical heat?
Disease control Recruiting nowThis trial tests whether a silicone film called Mepitel Film can prevent radiation dermatitis — painful skin irritation — in breast cancer patients undergoing radiation therapy in Singapore's hot and humid weather. About 60 adults who have had breast cancer surgery and are schedu…
Sponsor: National University Hospital, Singapore • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Can a new pill tame tough eczema? a large trial aims to find out
Disease control Recruiting nowThis phase 3 trial tests whether an experimental oral drug called VC005 can reduce eczema symptoms in adults with moderate to severe atopic dermatitis. Participants are randomly assigned to receive either a low or high dose of VC005 or a placebo. The main goal is to see if more p…
Phase: PHASE3 • Sponsor: Jiangsu vcare pharmaceutical technology co., LTD • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Skipping the armpit: a trial tests whether partial breast radiation alone is enough
Disease control Recruiting nowThis pilot study is testing whether partial breast irradiation alone — without first removing or sampling lymph nodes from the armpit — is safe for women age 40 and older with early-stage invasive breast cancer. All participants have had a lumpectomy but no sentinel node biopsy o…
Phase: NA • Sponsor: NYU Langone Health • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Steam mask vs. warm flannel: which melts away children's eyelid lumps faster?
Disease control Recruiting nowThis trial compares a steam mask — a fabric mask with self-hydrating beads heated in a microwave — to the traditional warm compress (a towel soaked in warm water) for treating chalazion, a common eyelid lump, in children aged 5 to 16. Researchers will measure whether the steam ma…
Phase: NA • Sponsor: University of Sheffield • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New drug aims to quiet chronic hives
Disease control Recruiting nowThis study tests an experimental drug called BBT001 in adults with chronic spontaneous urticaria, a condition causing frequent hives without a clear trigger. Participants receive multiple doses of BBT001 or a placebo to see if it is safe and helps control symptoms. The trial focu…
Phase: PHASE1, PHASE2 • Sponsor: Bambusa Therapeutics • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Gene therapy gel targets rare blistering skin disease
Disease control Recruiting nowThis early study tests a new gene therapy gel called KB111 for Hailey-Hailey disease, a rare genetic condition that causes painful blisters and skin lesions. The gel uses a modified virus to deliver a working copy of the faulty gene directly to the skin. The trial enrolls about 7…
Phase: EARLY_PHASE1 • Sponsor: Krystal Biotech, Inc. • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New eczema drug enters first human tests
Disease control Recruiting nowThis early-stage study tests a new drug called DCY636 for safety and tolerability in healthy volunteers and people with moderate to severe atopic dermatitis (eczema). The trial has two parts: a single dose in healthy adults and multiple doses in eczema patients. It aims to gather…
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New pill could regrow hair in severe alopecia – trial begins
Disease control Recruiting nowThis study tests a drug called deuruxolitinib in Japanese adults aged 18-65 with severe alopecia areata, an autoimmune condition causing significant scalp hair loss. Participants must have at least 50% hair loss. The trial measures how well the drug regrows hair and how satisfied…
Phase: PHASE3 • Sponsor: Sun Pharma Japan Limited • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat muscle disease
Disease control Recruiting nowThis phase 1 trial tests a new cell therapy called ICG318 CAR-T in adults with refractory inflammatory myopathy, a condition where the immune system attacks muscles, causing weakness and inflammation. The therapy uses a patient's own immune cells, engineered to target specific ma…
Phase: PHASE1 • Sponsor: iCell Gene Therapeutics • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Could a simple injection dissolve painful calcium lumps in rare diseases?
Disease control Recruiting nowThis study tests whether injecting sodium thiosulfate directly into abnormal calcium deposits can shrink them and reduce pain. It includes people with three rare conditions: systemic sclerosis, dermatomyositis, and a genetic disorder called iPPSD2. Participants receive up to 11 i…
Phase: PHASE2 • Sponsor: University Hospital, Limoges • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New shot could tame tough eczema by calming overactive immune cells
Disease control Recruiting nowThis study tests an experimental drug called rezpegaldesleukin (NKTR-358) for people aged 12 and older with moderate-to-severe atopic dermatitis, a type of eczema. Participants receive either the drug or a placebo as a shot under the skin. The goal is to see if the drug can clear…
Phase: PHASE3 • Sponsor: Nektar Therapeutics • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Laser rejuvenation may shield aging skin from cancer
Disease control Recruiting nowThis study tests whether a single session of fractionated laser resurfacing on one forearm can reduce precancerous spots (actinic keratosis) and prevent future non-melanoma skin cancers in older adults with fair skin. Participants are at least 60 years old and have had actinic ke…
Phase: NA • Sponsor: Wright State University • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Custom breast shell could make radiation therapy faster and more comfortable
Disease control Recruiting nowThis trial tests whether a custom-made breast holder called VENUS SHELL™ can improve positioning and comfort during radiotherapy for early-stage breast cancer. Participants lie on their stomach while the device holds the breast in place, aiming to deliver precise radiation in sho…
Phase: NA • Sponsor: HeroSupport SA • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New oral drug aims to restore skin color in vitiligo
Disease control Recruiting nowThis trial tests an experimental drug called QY201 in adults with non-segmental vitiligo, a condition that causes white patches on the skin. Participants take QY201 or a placebo tablet twice daily for 24 weeks. The main goal is to see if QY201 can reduce the amount of facial skin…
Phase: PHASE2 • Sponsor: E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Experimental drug combo aims to tackle tough lymphoma
Disease control Recruiting nowThis trial investigates whether combining two FDA-approved drugs, duvelisib and venetoclax, can safely and effectively treat peripheral T-cell lymphoma that has returned or stopped responding to prior therapies. The study enrolls adults who have tried at least two previous treatm…
Phase: PHASE1, PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New pill could help restore skin color in vitiligo patients
Disease control Recruiting nowThis study tests an experimental drug called D-2570 in 160 adults with non-segmental vitiligo, a condition that causes white patches on the skin. Participants take either D-2570 or a placebo pill once daily for 24 weeks, with an optional 24-week extension. The goal is to see if t…
Phase: PHASE2 • Sponsor: InventisBio Co., Ltd • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat autoimmune diseases
Disease control Recruiting nowThis early-stage trial tests an experimental cell therapy called NEUK203-215 in adults aged 18-65 with severe autoimmune diseases like lupus or scleroderma that have not responded to other treatments. The therapy uses immune cells from a healthy donor, engineered to target and at…
Phase: EARLY_PHASE1 • Sponsor: Neukio Biotherapeutics (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New pill shows promise for controlling painful skin condition in long-term trial
Disease control Recruiting nowThis phase 3 study tests the long-term safety and effectiveness of remibrutinib, an oral drug, in 710 adults with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition causing painful abscesses. Participants have already completed a prior remibrutinib study. …
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Vitamin e dressing may speed healing of bedsores
Disease control Recruiting nowThis trial tests whether a special dressing containing tocotrienols (a form of vitamin E) helps heal stage 1 and 2 pressure ulcers (bedsores) faster than standard care. About 114 adults with pressure ulcers will be randomly assigned to receive either the tocotrienol dressing or a…
Phase: NA • Sponsor: Monash University Malaysia • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Gene therapy for 'Butterfly Skin' disease tracked for 15 years in major safety registry
Disease control Recruiting nowThis registry follows people with recessive dystrophic epidermolysis bullosa (RDEB) who have been treated with prademagene zamikeracel, a gene therapy made from their own skin cells and surgically applied to wounds. The study monitors long-term safety and wound healing durability…
Sponsor: Abeona Therapeutics, Inc • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New wound dressings aim to heal stubborn diabetic and leg ulcers
Disease control Recruiting nowThis trial investigates whether two special wound dressings—one made from donated amniotic membrane and another from a synthetic material—can help heal diabetic foot ulcers and venous leg ulcers that have not responded to standard care. Adults aged 18 and older with these hard-to…
Phase: NA • Sponsor: Capsicure, LLC • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Could a simple walk improve heart health in behcet disease?
Disease control Recruiting nowThis study investigates whether a 12-week treadmill walking program can improve metabolic syndrome in women with Behcet disease. Participants walk for 40 minutes three times a week. Researchers measure changes in cholesterol, triglycerides, blood sugar, blood pressure, and waist …
Phase: NA • Sponsor: Cairo University • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New injection aims to tame tough eczema
Disease control Recruiting nowThis early-stage trial tests an investigational drug called SSGJ-716, given as an injection, to see if it is safe and tolerable. The study first enrolls healthy adults to test a single dose, then moves to people with moderate-to-severe atopic dermatitis (a type of eczema) who rec…
Phase: PHASE1 • Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Could shorter drug pauses before shoulder surgery reduce flares without raising infection risk?
Disease control Recruiting nowThis study looks at whether people with rheumatic diseases (like rheumatoid arthritis or lupus) can safely stop their immunosuppressant medications for a shorter time before elective shoulder replacement surgery. The goal is to see if this approach lowers the chance of disease fl…
Phase: PHASE2 • Sponsor: NYU Langone Health • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Can stem cell exosomes regrow hair? new trial investigates
Disease control Recruiting nowThis trial tests whether injections of human umbilical cord stem cell exosomes can regrow hair in men with male pattern baldness. Participants receive either the exosome treatment or a placebo injection into the scalp every four weeks for three sessions. The study measures change…
Phase: PHASE2 • Sponsor: Zhang Han • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Could a stool transplant ease gut woes in scleroderma?
Disease control Recruiting nowThis study tests whether transplanting healthy gut bacteria can relieve constipation and bloating in people with systemic sclerosis, an autoimmune disease that often affects the digestive tract. Participants will receive the bacteria either as capsules or as a retention enema. Th…
Phase: PHASE2 • Sponsor: The University of Texas Health Science Center, Houston • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New combo therapy takes on advanced cancers
Disease control Recruiting nowThis early-stage study tests a new drug called N-3C01, given alone or with an immunotherapy, in people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety, find the right dose, and see if the combination shrinks tumors. About 114 a…
Phase: PHASE1, PHASE2 • Sponsor: Hefei Xinzhu Biological Technology Co., Ltd. • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New eczema cream shows promise in major trial
Disease control Recruiting nowThis study tests a new cream called VC005 for people aged 12 and older with mild to moderate atopic dermatitis (eczema). The goal is to see if the cream can clear or nearly clear the skin rash better than a cream without medicine. About 360 participants will use either the study …
Phase: PHASE3 • Sponsor: Jiangsu vcare pharmaceutical technology co., LTD • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Psoriasis patients monitored for two years on newer biologic drug
Disease control Recruiting nowThis study watches 200 adults with moderate-to-severe plaque psoriasis who have never taken a biologic before. They are starting treatment with guselkumab, and researchers will track how many continue the drug for two years. The goal is to see how well people stick with this trea…
Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Could a histamine shot tame chronic hives?
Disease control Recruiting nowThis study looks at how well an injection called Immunoglobulin-Histamine complex (IHC, brand name Histoglob) works for people with chronic urticaria, or long-term hives. Researchers will track 600 patients in India to see if the treatment reduces hives and the need for other all…
Sponsor: Bharat Serums and Vaccines Limited • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Engineered immune cells take aim at blistering skin disease
Disease control Recruiting nowThis study investigates whether a single infusion of a patient's own genetically modified immune cells (CD19 CAR-T cells) can safely control moderate-to-severe pemphigus vulgaris that hasn't responded to standard treatments. The therapy targets and depletes B cells, which are tho…
Phase: NA • Sponsor: Jinbo Chen • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New targeted drug hopes to shrink NRAS-Driven cancers
Disease control Recruiting nowThis early-phase study tests a new oral drug, RLY-8161, designed to block a specific cancer-driving protein called NRAS. It is for people with advanced melanoma or other solid tumors that have an NRAS mutation and have not responded to standard treatments. The main goals are to f…
Phase: PHASE1 • Sponsor: Relay Therapeutics, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Combination therapy aims to boost response in rare skin cancers
Disease control Recruiting nowThis trial tests whether combining the drug mogamulizumab with low-dose total skin electron beam therapy works better than either alone for people with mycosis fungoides or Sezary syndrome, two rare types of skin lymphoma. Participants receive both treatments over several weeks. …
Phase: PHASE2 • Sponsor: Stanford University • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Can supplements boost healing after gum color surgery?
Disease control Recruiting nowThis study looks at whether taking coenzyme Q10 and vitamin C, alone or together, can improve healing and reduce dark gum color after surgical gum depigmentation. The trial involves 20 healthy adults with dark gums who undergo a simple scalpel procedure to remove pigmented tissue…
Phase: NA • Sponsor: Al-Azhar University • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New shot could zap skin cancer without surgery
Disease control Recruiting nowThis early-phase trial tests an injected drug called FLD-103 for nodular basal cell carcinoma, a common skin cancer. About 48 adults will receive either one or several injections directly into their tumor. The main goal is to check safety and find the right dose, while also seein…
Phase: PHASE1 • Sponsor: Feldan Therapeutics • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New oral pill aims to clear psoriasis in major trial
Disease control Recruiting nowThis phase 3 study tests whether the experimental drug WD-890 can safely improve skin clearance in adults with moderate to severe plaque psoriasis. Participants are randomly assigned to receive either WD-890 or a placebo tablet daily for up to 52 weeks. The main goals are to see …
Phase: PHASE3 • Sponsor: Zhejiang Wenda Pharma Technology LTD. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Can 'Supercharged' donor cells beat viruses that drugs Can't?
Disease control Recruiting nowThis study tests whether giving patients special donor immune cells (called CD45RA-depleted DLI) can treat viral infections that persist after a stem cell transplant. The trial involves 30 participants who have not improved with standard antiviral drugs. Researchers will measure …
Phase: PHASE1, PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Immune cells take on nerve tumors: new trial launches
Disease control Recruiting nowThis early-stage trial is testing whether specially engineered immune cells (called CAR-T and CTL cells) and a dendritic cell vaccine can safely treat people with neurofibromatosis or schwannomatosis, conditions that cause nerve tumors. The study will enroll 100 participants aged…
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New hope for bedsores: 2,000-Patient trial tests advanced wound matrices
Disease control Recruiting nowThis study tests whether adding special wound dressings (called CAMPs) to standard care helps heal pressure ulcers (bedsores) that won't close on their own. About 2,000 adults with stage 3 or 4 pressure sores will receive weekly applications of a CAMP product plus standard care, …
Phase: PHASE4 • Sponsor: Sequence LifeScience, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Could a simple ointment replace surgery for some skin cancers?
Disease control Recruiting nowThis study tests whether an ointment called tirbanubulin can effectively treat superficial basal cell carcinoma, a common type of skin cancer. Adults with small, previously untreated lesions on the body (not the face or scalp) apply the ointment once daily for five days. If the l…
Phase: PHASE2 • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Calorie cutting may reverse a key step toward diabetes
Disease control Recruiting nowThis study investigates whether reducing calories to lower fat in the liver and muscles can improve how the body responds to insulin. Researchers will measure changes in insulin sensitivity and fat levels in 250 healthy but insulin-resistant adults with a family history of type 2…
Phase: NA • Sponsor: Yale University • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Can a 3-Week radiation course beat 5 weeks for breast cancer patients with reconstruction?
Disease control Recruiting nowThis phase 3 trial tests whether a shorter, higher-dose radiation schedule (3 weeks) is as safe and effective as the standard 5-week schedule for women with high-risk breast cancer who have had a mastectomy and immediate implant reconstruction. The study will enroll 506 women and…
Phase: PHASE3 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New shampoo aims to stop head lice from coming back
Disease control Recruiting nowThis study tests a new shampoo (X92001483) that works by physically trapping and removing head lice, comparing it to a standard medicated rinse (Nix Cream Rinse with 1% permethrin). The goal is to see if the new shampoo is safe, effective at killing lice, and can prevent reinfest…
Phase: NA • Sponsor: Oystershell NV • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New shot aims to tame rare autoimmune disease
Disease control Recruiting nowThis early-phase trial tests a new drug called PRO-203, given as a single shot under the skin. First, healthy volunteers will check safety; then, people with systemic sclerosis (a rare autoimmune disease that hardens skin and organs) will receive the drug. The main goal is to see…
Phase: PHASE1, PHASE2 • Sponsor: Prolium Bioscience, Inc • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can a five-day ointment improve sun-damaged skin? new study investigates
Disease control Recruiting nowThis study follows adults with actinic keratosis (precancerous sun-damaged spots) on the face who are already using tirbanibulin ointment as part of their regular care. Researchers want to see if the treatment improves overall skin appearance and texture over 57 days. Participant…
Sponsor: Avant Health LLC • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Allergy drug dupilumab tested as potential hair loss treatment
Disease control Recruiting nowThis study tests whether dupilumab, a drug used for allergies and eczema, can help regrow hair in people with moderate-to-severe alopecia areata who also have allergies or high IgE levels. Participants receive weekly injections of dupilumab or a placebo for 48 weeks, followed by …
Phase: PHASE2 • Sponsor: Emma Guttman • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New Bandage-Like matrix could speed healing after skin cancer removal
Disease control Recruiting nowThis study tests a synthetic fiber matrix called Restrata, placed directly into surgical wounds after skin cancer removal. Researchers will track how long it takes for the wound bed to granulate (fill in with new tissue) and fully heal. The trial enrolls 34 adults with wounds bet…
Sponsor: Acera Surgical, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Bioactive glass may help seal the ear after cholesteatoma surgery
Disease control Recruiting nowThis trial tests whether a bioactive glass material can effectively fill the mastoid bone after surgery for cholesteatoma, a non-cancerous but destructive ear growth. Adults having their first cholesteatoma operation will receive the glass filler to stabilize the repair and preve…
Sponsor: Centre Hospitalier Intercommunal Creteil • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New radiation implant shows promise for skin cancer
Disease control Recruiting nowThis study tests a new device that delivers a special type of radiation directly into skin tumors. The goal is to see if it can shrink or control the cancer. The study is for adults with certain types of skin cancer, including squamous cell carcinoma and basal cell carcinoma. Par…
Phase: NA • Sponsor: Alpha Tau Medical LTD. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Alpha radiation seeds target tumors from the inside
Disease control Recruiting nowThis study tests a device called DaRT that delivers a unique type of radiation (alpha particles) directly into tumors. It is designed for people with certain skin cancers, mouth cancers, or soft tissue sarcomas that are accessible for direct injection. The goal is to see if this …
Phase: NA • Sponsor: Alpha Tau Medical LTD. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Cancer-Killing virus shows promise in early trial for advanced tumors
Disease control Recruiting nowThis early-phase trial is testing a new treatment called MEM-288, a virus designed to infect and kill cancer cells while also boosting the immune system. The study involves 40 adults with advanced solid tumors, including lung, skin, and breast cancers, who have not responded to s…
Phase: PHASE1 • Sponsor: Memgen, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
One-Week radiation for breast cancer: MRI precision may cut side effects
Disease control Recruiting nowThis study tests a new radiation approach for early breast cancer that uses real-time MRI guidance to deliver just three high-dose sessions over one week, instead of the usual several weeks. The goal is to see if this shorter treatment is safe, preserves the breast's appearance, …
Phase: PHASE2 • Sponsor: University of Wisconsin, Madison • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New shampoo regimen aims to soothe scalp after hair transplants
Disease control Recruiting nowThis study tests whether a special shampoo regimen can improve scalp health and reduce dandruff in 120 Chinese men who have had hair transplants. Some participants have mild-to-moderate seborrheic dermatitis (a common dandruff condition). The test group uses a special shampoo plu…
Phase: NA • Sponsor: ChinaNorm • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Drug combo aims to halt lung scarring in scleroderma
Disease control Recruiting nowThis trial tests whether adding rituximab to standard mycophenolate mofetil (MMF) therapy can improve lung function in people with severe lung scarring caused by systemic sclerosis. About 102 adults with this condition will receive either rituximab infusions plus MMF or placebo i…
Phase: PHASE3 • Sponsor: University Hospital, Tours • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Gene-Hacked immune cells take on tough cancers
Disease control Recruiting nowThis study tests a new treatment called IOV-4001 for people with advanced melanoma or non-small-cell lung cancer. The treatment uses a patient's own tumor-fighting immune cells, which are collected, genetically modified to remove a 'brake' called PD-1, and then infused back after…
Phase: PHASE1, PHASE2 • Sponsor: Iovance Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
CAR-T therapy takes on lupus and scleroderma in early trial
Disease control Recruiting nowThis early-phase trial is testing a new treatment called zamto-cel, a CAR-T cell therapy, for people with severe lupus or scleroderma that hasn't improved with standard treatments. The study will enroll 48 participants and primarily look at safety and side effects. Participants f…
Phase: PHASE1 • Sponsor: Miltenyi Biomedicine GmbH • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Two-Drug combo aims to tackle Hard-to-Treat T-Cell lymphoma
Disease control Recruiting nowThis phase 2 trial is testing whether combining two drugs—pembrolizumab (Keytruda) and brentuximab vedotin (Adcetris)—can shrink tumors in people with a type of T-cell lymphoma that has returned or not responded to at least one prior treatment. The study enrolls adults with CD30-…
Phase: PHASE2 • Sponsor: Yale University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Heat treatment could bring leishmaniasis care to local clinics
Disease control Recruiting nowThis study tests whether using a device that heats skin lesions to 50°C for 30 seconds can effectively treat cutaneous leishmaniasis in primary health centers in Ethiopia. 103 patients aged 12 to 60 with up to four lesions will receive thermotherapy and be monitored for 90 days. …
Phase: NA • Sponsor: Armauer Hansen Research Institute, Ethiopia • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Laser and steroid mouthwash aim to tame painful mouth sores in autoimmune disease
Disease control Recruiting nowThis study tests whether a steroid mouthwash (clobetasol propionate 0.05%) and low-level laser therapy, alone or together, can heal painful mouth sores in people with pemphigus vulgaris—a chronic autoimmune disease that causes blisters on skin and mucous membranes. Thirty partici…
Phase: NA • Sponsor: Damascus University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New laser could spark hair regrowth in balding patients
Disease control Recruiting nowThis pilot study tests a 1470nm laser on 10 adults with androgenetic alopecia (common baldness) or scarring alopecia. Researchers will measure hair density and counts using imaging, and track satisfaction. The goal is to see if the laser is safe and can improve hair growth.
Phase: NA • Sponsor: Montefiore Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Can stem cells heal burn scars? new trial aims to find out
Disease control Recruiting nowThis study tests whether injections of stem cells from donated fat tissue can improve the quality of old burn scars. 39 adults with hypertrophic scars (at least 2 years old) will receive stem cells in one scar area and a placebo in another. The main goal is to see if patients rep…
Phase: PHASE1, PHASE2 • Sponsor: Rigshospitalet, Denmark • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Small study to uncover how psoriasis drug tames the immune system
Disease control Recruiting nowThis study looks at how the drug tildrakizumab changes immune cells in the skin and blood of people with moderate-to-severe psoriasis. Ten adults will be treated and monitored for three months. The goal is to see how the drug reduces psoriasis severity and what happens to immune …
Phase: PHASE4 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug targets immune cells in scalp psoriasis
Disease control Recruiting nowThis study tests how guselkumab, a drug that blocks IL-23, affects immune cells in scalp psoriasis lesions. Ten adults with moderate-to-severe scalp psoriasis will receive treatment and have their scalp severity scores measured before and during treatment. The goal is to understa…
Phase: PHASE4 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Psoriasis drug trial aims to calm overactive immune cells
Disease control Recruiting nowThis study looks at how deucravacitinib, a drug that blocks a specific immune signal (TYK2), changes immune cells in the skin and blood of people with moderate-to-severe psoriasis. About 25 adults will take the drug and be monitored for improvements in their psoriasis symptoms. T…
Phase: PHASE4 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New pill for painful skin disease enters first human tests
Disease control Recruiting nowThis first-in-human trial tests an oral drug called SAR447971 (KT-485) in healthy volunteers and people with hidradenitis suppurativa (HS), a chronic skin condition causing painful lumps. The study has three parts: single and multiple doses in healthy people, and multiple doses i…
Phase: PHASE1 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Engineered immune cells take on Hard-to-Treat melanoma
Disease control Recruiting nowThis study tests a new treatment made from donor immune cells (CAR-NK cells) that are designed to attack two targets on melanoma cells. It is for adults with advanced melanoma that has spread or cannot be removed and has not responded to standard therapies. The goal is to find a …
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Can olive oil and nuts tame psoriasis? new study tests diet plus biologics
Disease control Recruiting nowThis study tests whether adding a Mediterranean diet (rich in olive oil, nuts, fish, and limited red meat) improves psoriasis symptoms in 36 adults who are about to start biologic therapy (Anti-IL-17 or Anti-IL-23 drugs). Participants are randomly assigned to either follow the di…
Phase: NA • Sponsor: University Hospitals Cleveland Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New hope for rare muscle disease: baricitinib trial aims to cut steroid use
Disease control Recruiting nowThis Phase 3 trial tests whether baricitinib, a JAK inhibitor pill, can improve symptoms of dermatomyositis (a rare autoimmune disease causing muscle weakness and skin rashes) while allowing patients to stop steroids. 62 adults with active disease will receive baricitinib or a pl…
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Baldness breakthrough? own cells injected into scalp to regrow hair
Disease control Recruiting nowThis study tests a new treatment called EPI-001 for androgenetic alopecia (common baldness). EPI-001 is made from a patient's own scalp cells and injected into the scalp. The trial has two parts: first, finding the safest dose in a small group, then comparing the best dose to a p…
Phase: PHASE1, PHASE2 • Sponsor: Epibiotech • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New shot could tame painful skin condition
Disease control Recruiting nowThis early-phase trial tests siplizumab, a drug given as a shot under the skin, in 12 adults with moderate-to-severe hidradenitis suppurativa (painful boils) that hasn't improved with standard treatments. The main goal is to see if the drug safely reduces the number of inflamed l…
Phase: EARLY_PHASE1 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New injection aims to tame stubborn autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a new drug, GT801, in 22 adults with moderate to severe autoimmune diseases that haven't responded to standard treatments. The main goals are to check safety and find the right dose. Researchers will also look for signs that the drug helps control the…
Phase: EARLY_PHASE1 • Sponsor: Vivacta Biotechnology (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Could a simple injection treat leg skin cancer?
Disease control Recruiting nowThis early-stage trial tests injecting a chemotherapy drug (5FU) directly into skin cancers on the lower legs, with or without a vitamin D-based cream (calcipotriene). The goal is to see if the treatment is safe and can shrink tumors. About 30 adults with small squamous cell carc…
Phase: PHASE1 • Sponsor: Melissa Pugliano-Mauro • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Vacuum dressing could cut infections after skin graft surgery
Disease control Recruiting nowThis study tests whether a vacuum dressing (negative pressure wound therapy) reduces infection compared to standard bandages after skin graft surgery for leg tumors. About 242 adults will be randomly assigned to one of the two dressings. The main goal is to see if the vacuum dres…
Phase: NA • Sponsor: Region Skane • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
Could a 2-Week radiation course replace longer treatment for skin cancer?
Disease control Recruiting nowThis study tests whether a short course of radiation (5 treatments over 2 weeks) can prevent cancer from coming back in people with high-risk head and neck skin cancer after surgery. For those with moderate-risk cancer, researchers want to see if simply monitoring them closely is…
Phase: PHASE2 • Sponsor: University of Vermont Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Laser light shows promise for thinning hair in new trial
Disease control Recruiting nowThis study is testing a device called Ultra that uses low-level laser light to help hair grow back. It involves 44 adults aged 22 to 70 with male or female pattern baldness. Participants will receive six laser treatments on their scalp, two weeks apart, and researchers will check…
Phase: NA • Sponsor: CynosureLutronic • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New pill could ease rare skin disease
Disease control Recruiting nowThis early-stage trial tests an oral drug called KM-023 for Olmsted Syndrome, a rare genetic condition causing painful, thick skin on the palms and soles. First, healthy volunteers will receive single or multiple doses to check safety and how the body handles the drug. Then, pati…
Phase: PHASE1 • Sponsor: Orvida Pharma (formerly Kamari Pharma) • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Could a stronger acne drug be better for darker skin? new trial aims to find out
Disease control Recruiting nowThis study compares giving oral isotretinoin (a strong acne medication) right away versus the usual antibiotics for moderate acne in people with darker skin (Fitzpatrick types IV-VI). The goal is to see if early use of isotretinoin reduces acne-related dark spots better than stan…
Phase: PHASE3 • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Placental grafts show promise for stubborn diabetic foot sores
Disease control Recruiting nowThis study tests whether a special placental graft, used alongside standard wound care, helps close diabetic foot ulcers that won't heal on their own. About 350 adults with type 1 or 2 diabetes and a foot ulcer between 1 and 15 cm² will be randomly assigned to get the graft plus …
Phase: PHASE4 • Sponsor: Sequence LifeScience, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New psoriasis drug tracked in everyday patients
Disease control Recruiting nowThis study follows 350 adults in France with moderate-to-severe plaque psoriasis who are starting deucravacitinib, a daily pill. Researchers will track how well the drug controls skin symptoms and improves quality of life over time in real-world settings, not a controlled lab env…
Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Could a Once-a-Week acne pill replace daily antibiotics?
Disease control Recruiting nowThis study compares a weekly dose of isotretinoin (a vitamin A derivative) to daily tetracycline antibiotics for treating moderate acne. Researchers want to see if the weekly approach works just as well, with fewer side effects and less reliance on antibiotics. The trial will enr…
Phase: EARLY_PHASE1 • Sponsor: Medical University of South Carolina • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Could a shorter antibiotic course be just as good for leg infections?
Disease control Recruiting nowThis phase 3 trial compares a 5-day course of the antibiotic flucloxacillin to the standard 7-day course for adults with leg cellulitis. About 334 participants will receive either 5 days of active drug plus 2 days of placebo, or 7 days of active drug. The goal is to see if the sh…
Phase: PHASE3 • Sponsor: University of Southampton • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Engineered immune cells aim to tame autoimmune diseases
Disease control Recruiting nowThis study tests a new treatment called QT-219CX, which uses specially engineered immune cells (CAR-T cells) to target and calm the overactive immune system in people with autoimmune diseases like lupus, kidney disease, and scleroderma. The treatment is given as a one-time infusi…
Phase: EARLY_PHASE1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Could a Low-Protein diet boost immunotherapy for melanoma?
Disease control Recruiting nowThis study is testing whether a low branched-chain amino acid (BCAA) diet, when combined with an immunotherapy drug (anti-PD-1), is safe and effective for people with stage III melanoma. About 80 participants will receive either the special diet or a normal diet alongside the imm…
Phase: NA • Sponsor: Xijing Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Hair loss pill for women? new trial tests oral minoxidil
Disease control Recruiting nowThis phase 3 trial tests whether a daily 1 mg minoxidil pill can treat female pattern hair loss as effectively as the standard topical minoxidil solution. About 520 women with hair thinning will be randomly assigned to receive either the oral pill, the topical solution, or a plac…
Phase: PHASE3 • Sponsor: Industrial Farmacéutica Cantabria, S.A. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Old drug, new hope: could filgotinib tame rare immune diseases?
Disease control Recruiting nowThis phase 2 trial is testing whether filgotinib, a drug already used for arthritis, can help people with three rare immune diseases: Behçet's disease, myositis, and IgG4-related disease. The goal is to see if it can control disease activity and reduce the need for long-term ster…
Phase: PHASE2 • Sponsor: UMC Utrecht • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
CAR t therapy takes on lupus, MS, and more in first human safety trial
Disease control Recruiting nowThis early-stage study tests a new treatment called HBI0101 CAR T for people with severe autoimmune diseases like lupus, multiple sclerosis, and rheumatoid arthritis that haven't improved with standard treatments. The main goal is to find a safe dose and check for side effects in…
Phase: PHASE1 • Sponsor: Polina Stepensky • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug B007 aims to tame pemphigus with fewer meds
Disease control Recruiting nowThis study tests a new drug called B007 in 132 people with pemphigus, a serious blistering skin disease. The goal is to see if B007 can help patients achieve complete remission while using minimal other treatments. Participants receive injections of B007 at high or low doses, and…
Phase: PHASE2, PHASE3 • Sponsor: Shanghai Jiaolian Drug Research and Development Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Could a shorter antibiotic course for lyme disease be just as effective?
Disease control Recruiting nowThis trial is testing whether a 7-day course of doxycycline works as well as the standard 14-day course for people with multiple erythema migrans, a sign of early Lyme disease. About 200 participants will be randomly assigned to one of the two treatment durations. Researchers wil…
Phase: NA • Sponsor: University Medical Centre Ljubljana • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New antibody drug aims to halt skin and hair loss
Disease control Recruiting nowThis early-stage trial tests a new drug called IBI3013, which blocks a protein (IL-15) involved in immune attacks. It includes 160 people: healthy volunteers first, then people with active vitiligo or severe alopecia areata. The main goal is to check safety and how the drug moves…
Phase: PHASE1 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New lotion shows promise for rare skin disorder
Disease control Recruiting nowThis study tests a lotion called QRX003 in people with Netherton Syndrome, a rare genetic skin condition. About 16 participants aged 4 and older will apply the lotion twice daily for 12 weeks. Researchers will check if it improves skin appearance and reduces itching.
Phase: PHASE2, PHASE3 • Sponsor: Quoin Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could a flower extract heal parasitic skin ulcers? new trial seeks answers
Disease control Recruiting nowThis phase 3 trial tests whether a plant-based tincture made from arnica flowers can safely and effectively heal skin ulcers caused by cutaneous leishmaniasis, a parasitic disease spread by sandflies. About 96 people aged 12 and older with confirmed infection will receive either …
Phase: PHASE3 • Sponsor: Universidad de Antioquia • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New imaging tool could make mouth biopsies more accurate
Diagnosis Recruiting nowThis study tests a new imaging device called the Active Biopsy Guidance System to help doctors decide when and where to take tissue samples (biopsies) from mouth lesions. About 90 adults with suspicious mouth spots or a history of oral cancer will participate. The goal is to see …
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Diagnosis
Last updated Aug 12, 2026 00:00 UTC
-
New PET tracers aim to light up Hard-to-See cancers
Diagnosis Recruiting nowThis early-phase study is testing two radioactive imaging agents, 68Ga-DFC413 and 68Ga-NNS309, to see how well they highlight tumors on PET scans. About 66 adults with advanced pancreatic, lung, breast, colorectal, or soft tissue cancers will receive the agents. The goal is to co…
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Diagnosis
Last updated Jul 30, 2026 00:00 UTC
-
A microchip implanted in tumors could reveal which drugs work best
Diagnosis Recruiting nowThis pilot study tests a small microdevice that is temporarily placed inside a skin lesion to release up to 19 different cancer drugs at once. The goal is to see if the device can safely and effectively show which drugs kill the cancer cells in that specific patient. The study in…
Phase: NA • Sponsor: Dana-Farber Cancer Institute • Aim: Diagnosis
Last updated Jul 29, 2026 00:00 UTC
-
Fast new swab test could speed up vaginitis diagnosis
Diagnosis Recruiting nowThis study will test a new diagnostic device called the Nanopath assay, which aims to quickly detect bacteria or yeast causing vaginitis. Up to 1000 women with symptoms like itching or discharge will provide vaginal swab samples, either collected by a clinician or themselves. The…
Sponsor: Nanopath, Inc • Aim: Diagnosis
Last updated Jul 22, 2026 00:00 UTC
-
New PET tracer aims to spot hidden cancer spread in the abdomen
Diagnosis Recruiting nowThis phase 2 study tests whether a radioactive tracer called [68Ga]BED003 can improve PET/CT scans for detecting cancer in the peritoneum (the lining of the abdomen). The trial includes adults with colorectal, ovarian, gastric, pancreatic, or a type of breast cancer. Researchers …
Phase: PHASE2 • Sponsor: Blue Earth Diagnostics • Aim: Diagnosis
Last updated Jul 17, 2026 00:00 UTC
-
New PET scan tracer could spot keloids without a biopsy
Diagnosis Recruiting nowThis study is testing whether a special PET-CT scan using a radioactive tracer called 68Ga-RGD can help doctors diagnose keloids and see how well treatment is working. Keloids are raised scars that grow beyond the original wound, and current diagnosis relies on physical exams. Th…
Phase: PHASE1, PHASE2 • Sponsor: Peking Union Medical College Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 14:01 UTC
-
Could a scan replace surgery for breast cancer staging?
Diagnosis Recruiting nowThis study tests whether a special PET/MRI scan can accurately detect if breast cancer has spread to lymph nodes in the armpit, potentially replacing the need for surgical removal of those nodes. About 119 women with certain types of breast cancer (luminal A or lobular) will get …
Phase: PHASE2 • Sponsor: Università Vita-Salute San Raffaele • Aim: Diagnosis
Last updated Jun 27, 2026 13:06 UTC
-
Phone AI could spot eye disease in remote areas
Diagnosis Recruiting nowThis study tests a smartphone app that uses artificial intelligence to detect 16 different eye diseases from photos taken with the phone. The AI works entirely on the device, so no internet is needed. Researchers will compare its accuracy to eye doctors and see if non-medical use…
Sponsor: Zhongshan Ophthalmic Center, Sun Yat-sen University • Aim: Diagnosis
Last updated Jun 27, 2026 13:05 UTC
-
New scan aims to uncover hidden breast cancer in early stage patients
Diagnosis Recruiting nowThis study tests a new imaging method called FAPI-PET/MRI to see if it can detect hidden invasive breast cancer in 30 people diagnosed with ductal carcinoma in situ (DCIS), a common pre-stage of breast cancer. Participants receive a weakly radioactive drug and lie in a scanner fo…
Phase: PHASE2 • Sponsor: Universität Münster • Aim: Diagnosis
Last updated Jun 27, 2026 13:01 UTC
-
Laser pen could measure skin cancer size without cutting
Diagnosis Recruiting nowThis pilot study is testing whether a handheld laser probe, called Raman spectroscopy, can measure the size of skin cancer tumors. Twenty people with basal or squamous cell carcinoma who are already scheduled for brachytherapy will have their tumors scanned with the probe. The go…
Sponsor: Tiezhi Zhang • Aim: Diagnosis
Last updated Jun 27, 2026 12:31 UTC
-
Can a baseball league program help prevent skin cancer in rural kids?
Prevention Recruiting nowThis study tests a sun protection program for children playing baseball in rural Utah and West Virginia. Researchers will observe whether kids on teams using the program apply sunscreen, wear hats and long sleeves, and seek shade more often than those on teams that don't. The goa…
Phase: NA • Sponsor: University of Utah • Aim: Prevention
Last updated Aug 12, 2026 00:00 UTC
-
Can text messages and facebook groups prevent skin cancer in teens?
Prevention Recruiting nowThis pilot study tests a digital program called Sun Safe Together (SST) designed to improve sun safety habits in teenagers and their parents. Teens receive text messages about sun protection for 12 weeks, while parents join a private Facebook group with related content. The study…
Phase: NA • Sponsor: Rutgers, The State University of New Jersey • Aim: Prevention
Last updated Aug 07, 2026 00:00 UTC
-
Can fish oil boost Tamoxifen's power to prevent breast cancer?
Prevention Recruiting nowThis study tests whether adding high-dose omega-3 fatty acids to low-dose tamoxifen can lower breast cancer risk more than tamoxifen alone. It includes 66 overweight or obese postmenopausal women at increased risk for breast cancer. The goal is to see if the combination improves …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Prevention
Last updated Aug 06, 2026 00:00 UTC
-
Can fatty acids beat dressings to stop bedsores in prone patients?
Prevention Recruiting nowThis study compares two methods to prevent pressure ulcers (bedsores) in critically ill patients who must lie face-down (prone) for breathing support. About 262 ICU patients will receive either hyperoxygenated fatty acids or hydrocolloid dressings on at-risk areas. The goal is to…
Phase: NA • Sponsor: Puerta de Hierro University Hospital • Aim: Prevention
Last updated Jul 26, 2026 00:00 UTC
-
Laser resurfacing may shield aging skin from cancer
Prevention Recruiting nowThis study tests whether a laser treatment called fractionated laser resurfacing (FLR) can protect the forearms of older adults from precancerous spots (actinic keratoses) and non-melanoma skin cancer. Participants are 60 or older with fair skin and at least five precancerous spo…
Phase: NA • Sponsor: Wright State University • Aim: Prevention
Last updated Jul 18, 2026 00:00 UTC
-
Blood thinner may stop autoimmune disease before it starts
Prevention Recruiting nowThis trial tests whether clopidogrel, a common blood thinner, can prevent systemic sclerosis (scleroderma) in people who have Raynaud phenomenon and specific antibodies that put them at high risk. About 47% of such individuals develop full scleroderma within five years. Participa…
Phase: PHASE2, PHASE3 • Sponsor: University Hospital, Bordeaux • Aim: Prevention
Last updated Jul 09, 2026 00:00 UTC
-
Shingles breakthrough? calcitonin shots aim to stop chronic pain before it starts
Prevention Recruiting nowThis phase 3 trial tests whether adding daily calcitonin injections to standard shingles treatment can prevent postherpetic neuralgia, a painful nerve condition that can last for months or years. Researchers will enroll 168 adults aged 50 and older who have had a shingles rash fo…
Phase: PHASE3 • Sponsor: Tanta University • Aim: Prevention
Last updated Jul 08, 2026 00:00 UTC
-
Could a probiotic cream shield cancer patients from radiation burns?
Prevention Recruiting nowThis early-stage trial tests a cream made from inactivated Akkermansia muciniphila bacteria to prevent skin injury in 40 breast or head/neck cancer patients receiving radiation. The cream is applied three times daily to the radiation area. The main goal is to see if it is safe an…
Phase: PHASE1 • Sponsor: West China Hospital • Aim: Prevention
Last updated Jun 27, 2026 13:04 UTC
-
Shingles vaccine protection tested over 6 years in 24,740 adults
Prevention Recruiting nowThis study looks at how well a live shingles vaccine prevents shingles over 6 years in adults aged 40 and older. It follows about 24,740 people who were in an earlier vaccine trial, comparing those who got the vaccine first to those who got it later. Researchers will track new sh…
Sponsor: Jiangsu Province Centers for Disease Control and Prevention • Aim: Prevention
Last updated Jun 27, 2026 12:33 UTC
-
Can a common antiseptic spray stop radiation burns in cancer patients?
Prevention Recruiting nowThis study tests whether a chlorhexidine spray can prevent severe skin reactions caused by radiation therapy in people with nasopharyngeal cancer. About 148 participants will use the spray or a placebo during their treatment. The goal is to see if the spray reduces the chance of …
Phase: PHASE3 • Sponsor: Jiangxi Provincial Cancer Hospital • Aim: Prevention
Last updated Jun 27, 2026 12:26 UTC
-
New drug aims to ease painful mouth sores for head and neck cancer patients
Symptom relief Recruiting nowThis phase II trial tests whether adding BMX-001 to standard symptom management can reduce severe mouth sores in head and neck cancer patients receiving chemoradiation. About 98 participants will receive either BMX-001 or a placebo alongside usual care. The goal is to see if BMX-…
Phase: PHASE2 • Sponsor: NRG Oncology • Aim: Symptom relief
Last updated Aug 18, 2026 03:00 UTC
-
New eczema drug enters first human tests
Symptom relief Recruiting nowThis early-stage trial is testing a new injectable drug called ARQ-234 in healthy volunteers and people with moderate to severe eczema. The main goals are to check safety and how the body processes the drug, while also looking for early signs that it might improve eczema symptoms…
Phase: PHASE1 • Sponsor: Arcutis Biotherapeutics, Inc. • Aim: Symptom relief
Last updated Aug 18, 2026 03:00 UTC
-
New hope for painful skin condition: experimental drug LAD328 enters phase 2 trial
Symptom relief Recruiting nowThis study tests whether the experimental drug LAD328 can reduce symptoms of hidradenitis suppurativa, a chronic skin condition causing painful lumps. About 50 adults with moderate-to-severe disease will receive either LAD328 or a placebo. The main goal is to see if the drug lead…
Phase: PHASE2 • Sponsor: Almirall, S.A. • Aim: Symptom relief
Last updated Aug 18, 2026 03:00 UTC
-
A new gel aims to fade dark Spots—Will it deliver a brighter complexion?
Symptom relief Recruiting nowThis trial tests whether a depigmenting gel cream called Blancy Pro can reduce facial hyperpigmentation, including dark spots and melasma. Forty women aged 30 to 60 will apply the product daily for 90 days. Researchers will measure skin lightening using a colorimeter and clinical…
Phase: NA • Sponsor: Brainfarma Industria Química e Farmacêutica S/A • Aim: Symptom relief
Last updated Aug 18, 2026 03:00 UTC
-
Which workout wins for breast cancer recovery? a trial puts cardio vs conditioning to the test
Symptom relief Recruiting nowThis study tests whether two different exercise programs—one combining resistance training with cardio, the other with conditioning—have similar effects on muscle mass, fat mass, and blood pressure in women who have completed breast cancer treatment. Participants will exercise th…
Phase: NA • Sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) • Aim: Symptom relief
Last updated Aug 18, 2026 03:00 UTC
-
New pill could ease severe eczema itch and rash
Symptom relief Recruiting nowThis study tests an experimental daily tablet (PF-08049820) for adults with moderate to severe eczema (atopic dermatitis). About 165 participants will take either the study drug or a placebo for 12 weeks. Researchers will check skin improvement, itching, and safety through clinic…
Phase: PHASE2 • Sponsor: Pfizer • Aim: Symptom relief
Last updated Aug 18, 2026 03:00 UTC
-
New study tests online therapy to ease stress for parents of kids with RASopathies
Symptom relief Recruiting nowThis study tests whether Acceptance and Commitment Therapy (ACT), delivered through a smartphone app, can help caregivers of children with RASopathies (like Neurofibromatosis type 1 and Noonan syndrome) cope with parenting stress. The trial is fully remote and involves 70 adult c…
Phase: NA • Sponsor: National Cancer Institute (NCI) • Aim: Symptom relief
Last updated Aug 16, 2026 00:00 UTC
-
Ear stimulation device could tame rosacea flushing
Symptom relief Recruiting nowThis pilot study will test whether a device that gently stimulates a nerve in the ear (taVNS) can reduce facial redness and flushing in people with rosacea. Ten adults with moderate-to-severe rosacea will use the device daily for 4 weeks, then be followed for another 4 weeks to s…
Phase: NA • Sponsor: Brigham and Women's Hospital • Aim: Symptom relief
Last updated Aug 16, 2026 00:00 UTC
-
Can heat melt away lipomas without a scalpel?
Symptom relief Recruiting nowThis trial tests whether radiofrequency ablation (RFA) can safely and effectively treat superficial lipomas—benign fatty lumps under the skin—without leaving a scar. Instead of cutting out the lipoma, a thin needle delivers heat to melt it, guided by ultrasound. The study will me…
Phase: NA • Sponsor: Columbia University • Aim: Symptom relief
Last updated Aug 16, 2026 00:00 UTC
-
New cream targets itch in eczema patients
Symptom relief Recruiting nowThis study tests a cream called roflumilast 0.15% for itching in people with mild to moderate atopic dermatitis (eczema). About 40 participants aged 12 and older will apply the cream once daily for 4 weeks. Researchers will track how patients describe their itch and other skin se…
Phase: PHASE4 • Sponsor: Integrative Skin Science and Research • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
New eczema drug enters first human tests
Symptom relief Recruiting nowThis early-stage study tests a new drug called BBT001 in healthy volunteers and adults with moderate-to-severe atopic dermatitis (eczema). The main goal is to check safety and how the drug moves through the body. About 198 participants will receive either BBT001 or a placebo, wit…
Phase: PHASE1 • Sponsor: Bambusa Therapeutics • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
Could a Cardamom-Bacteria spray soothe your eczema?
Symptom relief Recruiting nowThis study tests if a spray made from ground cardamom seeds and a harmless skin bacteria (Roseomonas mucosa) can improve eczema symptoms in people aged 2 and older. Participants apply the spray 2-3 times a week for 14 weeks and are monitored remotely for about 7 months. Half rece…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
New gel could ease pain and heal wounds for kids with butterfly skin
Symptom relief Recruiting nowThis study tests a gel called TCP-25 on people with epidermolysis bullosa (EB), a condition that causes fragile skin and painful blisters. About 32 people aged 4 and older with certain types of EB will have two matching wounds treated—one with the study gel and one with a placebo…
Phase: PHASE2 • Sponsor: Xinnate AB • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
Can a new laser erase acne scars without harming darker skin?
Symptom relief Recruiting nowThis trial tests whether a hybrid fractional laser can safely and effectively reduce acne scars in people with skin of color. About 50 adults with acne scarring will receive the laser treatment and be followed for nine months. Researchers will measure changes in scar severity, pa…
Phase: NA • Sponsor: Montefiore Medical Center • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC
-
New psoriasis drug shows promise in Mid-Stage trial
Symptom relief Recruiting nowThis study tests a new medicine called ORKA-002 for adults with moderate-to-severe plaque psoriasis. About 160 participants will receive either the drug or a placebo to see if it clears skin and is safe. The goal is to find the best dose and check for side effects over 16 weeks.
Phase: PHASE2 • Sponsor: Oruka Therapeutics, Inc. • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC
-
Can a daily probiotic soothe colicky babies and calm eczema?
Symptom relief Recruiting nowThis trial tests whether giving formula-fed infants under 5 months a daily probiotic (Bifidobacterium bifidum) can reduce crying time by at least half in babies with colic, and also improve eczema symptoms. Over 8 weeks, half the babies receive the probiotic drops and half receiv…
Phase: NA • Sponsor: University of Roma La Sapienza • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC
-
Smart bandage zaps chronic wounds to speed healing
Symptom relief Recruiting nowThis pilot study tests a new flexible bandage called exciflex that delivers mild electrical stimulation to chronic wounds that won't heal normally. The study includes 16 veterans with diabetes or spinal cord injury who have lower leg wounds. The bandage is designed to work for up…
Phase: NA • Sponsor: VA Office of Research and Development • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC
-
Can a meditation app soothe teen eczema?
Symptom relief Recruiting nowThis trial tests whether regular use of a digital mindfulness meditation app can help adolescents aged 12-17 with moderate to severe atopic dermatitis (eczema) improve disease control and quality of life. Participants will use the app for 10-15 minutes, 3-4 times a week, while a …
Phase: NA • Sponsor: Weill Medical College of Cornell University • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC
-
Can coconut oil calm acne without irritating sensitive skin?
Symptom relief Recruiting nowThis study tests a 4-week skincare routine made with coconut oil to see if it safely and effectively manages mild to moderate acne in people with sensitive skin. Participants will use a cleanser, toner, serum, and day cream, with skin assessments at the start and end of the trial…
Phase: NA • Sponsor: USMARI Research & Innovation Centre • Aim: Symptom relief
Last updated Aug 08, 2026 00:03 UTC
-
Light therapy put to the test for stubborn leg wounds
Symptom relief Recruiting nowThis trial tests whether infrared laser therapy can relieve pain and speed healing in people with chronic venous leg ulcers — slow-healing wounds on the lower leg caused by poor blood flow. About 20 adults with ulcers lasting more than four weeks will receive either real laser tr…
Phase: NA • Sponsor: Wake Forest University Health Sciences • Aim: Symptom relief
Last updated Jul 31, 2026 00:00 UTC
-
Can a precise nerve block stop shingles pain before it becomes chronic?
Symptom relief Recruiting nowThis trial compares two ultrasound-guided nerve blocks — the midpoint transverse process to pleura (MTP) block and the erector spinae plane (ESP) block — for treating acute pain from shingles (herpes zoster) on the chest. About 90 adults with moderate to severe pain will receive …
Phase: NA • Sponsor: Tanta University • Aim: Symptom relief
Last updated Jul 31, 2026 00:00 UTC
-
Can a new drug called ZP9830 calm psoriasis Flare-Ups?
Symptom relief Recruiting nowThis trial investigates whether an experimental drug, ZP9830, can safely improve symptoms of plaque psoriasis when taken over 8 weeks. The study includes adults with stable plaque psoriasis who have at least two visible plaques. Researchers will monitor side effects, measure how …
Phase: PHASE1 • Sponsor: Zealand Pharma • Aim: Symptom relief
Last updated Jul 31, 2026 00:00 UTC
-
Core strength may unlock a faster tennis serve – a trial puts it to the test
Symptom relief Recruiting nowThis trial tests whether adding core muscle training to a standard shoulder strengthening program can improve flat serve ball speed and accuracy in recreational tennis players aged 18-35. Participants are randomly assigned to shoulder training plus a sham core routine, combined c…
Phase: NA • Sponsor: Cairo University • Aim: Symptom relief
Last updated Jul 31, 2026 00:00 UTC
-
A breath of relief? essential oils tested for wound care anxiety
Symptom relief Recruiting nowThis pilot trial tests whether inhaling a blend of Asian essential oils (Basil, Elemi, Calamansi) can reduce anxiety and pain in people with venous leg ulcers undergoing a wound-cleaning procedure called conservative sharp wound debridement. About 40 participants will be randomly…
Phase: NA • Sponsor: Singapore General Hospital • Aim: Symptom relief
Last updated Jul 30, 2026 00:00 UTC
-
Can a urea cream beat vaseline for nail psoriasis?
Symptom relief Recruiting nowThis study tests a cream called PROXERA PSOMED 30, which contains 30% urea, for treating nail psoriasis. 21 adults with nail psoriasis will apply the cream to one nail and Vaseline to another nail twice daily for 24 weeks. Researchers will compare how much each nail improves usin…
Phase: NA • Sponsor: ICIM International S.r.l. • Aim: Symptom relief
Last updated Jul 30, 2026 00:00 UTC
-
Could a flower extract help heal irritated skin faster?
Symptom relief Recruiting nowThis study tests whether a cream made with Helichrysum italicum (Immortelle) extract can help heal irritated skin and restore the skin barrier better than a plain moisturizer. Healthy volunteers will have a small patch of skin irritated with a mild soap, then apply the Immortelle…
Phase: NA • Sponsor: University of Split, School of Medicine • Aim: Symptom relief
Last updated Jul 19, 2026 00:00 UTC
-
Braids and conditioner may boost scalp cooling against chemo hair loss
Symptom relief Recruiting nowThis study tests whether special hairstyling methods — like braids, cornrows, or a conditioner-and-water mix — can help scalp cooling caps work better to prevent hair loss during chemotherapy. It focuses on people with curly or kinky hair (types 3 and 4), who have been underrepre…
Phase: NA • Sponsor: Montefiore Medical Center • Aim: Symptom relief
Last updated Jul 18, 2026 00:00 UTC
-
Could cutting calories quiet the ringing? diet trial targets tinnitus in behcet disease
Symptom relief Recruiting nowThis study investigates whether a 12-week low-calorie diet can reduce tinnitus (ringing in the ears) in people who have both Behcet disease and obesity. Twenty participants will follow the diet, and researchers will measure changes in tinnitus severity, discomfort, and quality of…
Phase: NA • Sponsor: Cairo University • Aim: Symptom relief
Last updated Jul 16, 2026 00:00 UTC
-
Could an ALS drug clear the fog of chemo brain?
Symptom relief Recruiting nowThis study tests whether riluzole, a drug already used for ALS, can help cancer survivors who struggle with memory, focus, and mental clarity after treatment — a condition called cancer-related cognitive impairment. Researchers will measure changes in a brain protein called BDNF …
Phase: PHASE2 • Sponsor: University of California, Irvine • Aim: Symptom relief
Last updated Jul 16, 2026 00:00 UTC
-
New gel could soothe eczema symptoms in early trial
Symptom relief Recruiting nowThis study tests a gel called VC005 on adults with mild to moderate atopic dermatitis (eczema). About 120 participants will use either the gel or a placebo to see if it safely reduces skin redness, itching, and rash. The goal is to ease symptoms, not cure the condition.
Phase: PHASE2 • Sponsor: Jiangsu vcare pharmaceutical technology co., LTD • Aim: Symptom relief
Last updated Jul 09, 2026 00:00 UTC
-
Can a smartphone app ease the misery of eczema, psoriasis, and hives?
Symptom relief Recruiting nowThis study tests whether a mobile app that provides psychological tools can improve quality of life for people with eczema, psoriasis, or chronic hives. Participants use the app over 32 weeks to learn coping strategies and wellness tips. The goal is to see if this digital approac…
Phase: NA • Sponsor: National University Hospital, Singapore • Aim: Symptom relief
Last updated Jul 03, 2026 00:00 UTC
-
Can a tailored exercise and diet plan beat cancer fatigue?
Symptom relief Recruiting nowThis study tests a personalized program combining exercise and nutrition advice to help reduce fatigue in people with indolent (slow-growing) lymphomas, such as chronic lymphocytic leukemia and follicular lymphoma. Participants receive an individualized exercise plan and dietary …
Phase: NA • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Symptom relief
Last updated Jul 03, 2026 00:00 UTC
-
Can sunscreen do more than protect? study tests if it fades dark spots
Symptom relief Recruiting nowThis study tests whether two types of facial sunscreen (untinted and tinted) can improve dark spots caused by melasma, sun spots, or post-inflammatory hyperpigmentation. Adult participants with mild to moderate dark spots apply the sunscreen at least twice daily for 56 days. Rese…
Phase: NA • Sponsor: Kenvue Brands LLC • Aim: Symptom relief
Last updated Jul 03, 2026 00:00 UTC
-
Laser showdown: which light best zaps spider veins?
Symptom relief Recruiting nowThis study compares two laser treatments—Nd:YAG versus diode—both combined with injection sclerotherapy, for removing reticular veins and spider veins (telangiectasias) using the CLaCS technique. About 80 adults aged 18 to 60 with these veins will receive one of the two laser typ…
Phase: NA • Sponsor: Ain Shams University • Aim: Symptom relief
Last updated Jul 03, 2026 00:00 UTC
-
Exercise after breast reconstruction: a new path to faster recovery?
Symptom relief Recruiting nowThis study looks at whether a structured 12-week exercise program can improve fitness and recovery in women who have had DIEP flap breast reconstruction after mastectomy. Half of the 78 participants will follow the exercise program, while the other half will receive standard care…
Phase: NA • Sponsor: Royal College of Surgeons, Ireland • Aim: Symptom relief
Last updated Jun 28, 2026 00:00 UTC
-
Simple breathing exercises could help behcet patients breathe easier after lung surgery
Symptom relief Recruiting nowThis study tests whether a 12-week program of daily breathing exercises can improve lung function and reduce fatigue in adolescents with Behcet disease who have had lung surgery. Forty participants will do inspiratory muscle training at home, six days a week. Researchers will mea…
Phase: NA • Sponsor: Cairo University • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
New eczema ointment shows promise in early trial
Symptom relief Recruiting nowThis study tests an ointment called HL-300 in people with mild-to-moderate atopic dermatitis (eczema). About 156 adults will apply the ointment or a placebo twice daily for 4 weeks. Researchers will check if the ointment reduces eczema severity and improves symptoms.
Phase: PHASE1, PHASE2 • Sponsor: Hangzhou Highlightll Pharmaceutical Co., Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
Can sound waves tighten your neck? new trial aims to find out
Symptom relief Recruiting nowThis study tests if the Ulthera System, a non-invasive ultrasound device, can safely improve sagging skin on the lower face, under the chin, and neck. About 218 adults with mild to moderate skin laxity will receive treatment or no treatment, and results will be measured at 90 day…
Phase: NA • Sponsor: Merz North America, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
App-Based breathing training aims to boost lung cancer recovery
Symptom relief Recruiting nowThis study tests whether using a mobile app that gives visual feedback can help lung cancer patients do breathing exercises more effectively after having part of a lung removed. Forty patients will try both standard breathing training and app-guided training on the same day. Rese…
Phase: NA • Sponsor: Hacettepe University • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Can a special cream soothe rosacea redness?
Symptom relief Recruiting nowThis study tests whether a facial cream containing SenSiCel™ can improve rosacea symptoms like redness and bumps. Seventy-six Chinese women with mild-to-moderate rosacea will use the cream or their usual moisturizer for 8 weeks. Doctors will check their skin at several visits to …
Phase: NA • Sponsor: ChinaNorm • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
Can a simple injection tighten loose skin after major weight loss?
Symptom relief Recruiting nowThis study tests whether injections of Poly-L-lactic acid (PLLA) can improve skin laxity in people who have loose skin after bariatric surgery. Fifteen participants receive three injections in one thigh over three months, while the other thigh is left untreated. During later plas…
Phase: NA • Sponsor: Nordberg Medical Italy srl • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
Can facial exercises ease the stiffness of scleroderma?
Symptom relief Recruiting nowThis study tests whether a personalized facial rehabilitation program can help people with systemic sclerosis who have facial tightness and mouth problems. About 60 adults with this rare autoimmune disease will either receive the rehab program or standard care. The goal is to see…
Phase: NA • Sponsor: University Hospital, Strasbourg, France • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
New mineral spray shows promise for faster wound healing
Symptom relief Recruiting nowThis early study is testing a mineral-based spray called THERAVEX on 26 people with various wounds, including burns, pressure sores, and diabetic ulcers. The spray is used alongside standard wound care to see if it helps the skin heal better and faster. So far, it appears safe an…
Sponsor: Biointelligent Technology Systems SL • Aim: Symptom relief
Last updated Jun 27, 2026 13:03 UTC
-
Can a common plant compound help rare telomere disease?
Symptom relief Recruiting nowThis pilot study tests whether quercetin, a natural antioxidant found in many plants, is safe for people with Dyskeratosis congenita or telomere biology disorders. Twelve participants will take quercetin for 24 weeks while researchers monitor side effects and how well people stic…
Phase: PHASE1 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Symptom relief
Last updated Jun 27, 2026 13:03 UTC
-
Skincare breakthrough? new study tests niacinamide creams for dark spots in black women
Symptom relief Recruiting nowThis study is testing whether a daily skincare routine with niacinamide and bioceramides can reduce facial dark spots (post-inflammatory hyperpigmentation) and improve self-esteem and quality of life in 60 Black women with darker skin tones. Participants will use a cleanser, mois…
Phase: NA • Sponsor: Hospital Israelita Albert Einstein • Aim: Symptom relief
Last updated Jun 27, 2026 13:02 UTC
-
Dissolvable vs Non-Dissolvable stitches: which leaves a better scar on darker skin?
Symptom relief Recruiting nowThis study compares two types of stitches (dissolvable fast gut and non-dissolvable polypropylene) to see which leads to less scarring and pigment changes in people with darker skin. Each participant's wound is split in half, with one stitch type on each side, and scarring is mea…
Phase: NA • Sponsor: Melissa Pugliano-Mauro • Aim: Symptom relief
Last updated Jun 27, 2026 13:02 UTC
-
New painkiller oliceridine tested against morphine in back surgery patients
Symptom relief Recruiting nowThis study compares a newer painkiller called oliceridine with two standard drugs, morphine and sufentanil, for pain relief after lumbar spine surgery. Ninety adults will receive one of the three drugs through a patient-controlled pump. The main goal is to see how well each drug …
Phase: NA • Sponsor: Anqing Municipal Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 13:02 UTC
-
New oral spray aims to ease sore throat and canker sores without drugs
Symptom relief Recruiting nowThis study is testing an oral spray called OROSEDAL to see if it helps relieve pain from sore throats, canker sores, and other minor mouth lesions. About 124 children and adults will use the spray as prescribed and report their pain levels over 6 days. The spray works by forming …
Sponsor: Laboratoires Elerte • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Mindfulness may soothe psoriasis stress
Symptom relief Recruiting nowThis study tests whether Mindfulness-Based Cognitive Therapy (MBCT) can reduce psychological distress and improve self-compassion in people with psoriasis. Researchers will enroll 128 adults with psoriasis who are experiencing emotional difficulties. Participants will either rece…
Phase: NA • Sponsor: Islamia University of Bahawalpur • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
New wound wash could speed ulcer healing
Symptom relief Recruiting nowThis study tests a new liquid treatment for chronic wounds like leg and foot ulcers. The goal is to clean the wound by removing dead tissue and bacteria, which may help it heal. About 80 people aged 60 and older will be randomly assigned to get either the new treatment or a stand…
Phase: NA • Sponsor: Universidad del Desarrollo • Aim: Symptom relief
Last updated Jun 27, 2026 12:38 UTC
-
Light therapy may soothe radiation burns in breast cancer patients
Symptom relief Recruiting nowThis study tests whether a special light therapy can reduce skin damage caused by radiation treatment in women with breast cancer. 60 women who have had breast-conserving surgery and are scheduled for radiation will either receive standard skin care alone or standard care plus po…
Phase: NA • Sponsor: Beni-Suef University • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC
-
Could a probiotic boost yeast infection treatment?
Symptom relief Recruiting nowThis study tests whether adding a probiotic supplement (Bioithas WOMAN®) to standard antifungal medicine helps relieve symptoms of vaginal yeast infections faster. About 60 women with suspected yeast infections will take either antifungal treatment alone or with the probiotic for…
Phase: NA • Sponsor: Bioithas SL • Aim: Symptom relief
Last updated Jun 27, 2026 12:36 UTC
-
Vitamin c shots may replace the knife for dark gums
Symptom relief Recruiting nowThis study tests if injecting vitamin C and glutathione into dark gums can lighten them as well as surgery. About 30 adults with gum pigmentation will be randomly assigned to either injection or scalpel removal. The main goal is to see how much the color improves, and the study a…
Phase: PHASE2 • Sponsor: Cairo University • Aim: Symptom relief
Last updated Jun 27, 2026 12:36 UTC
-
New pain block may cut opioid use after lung surgery
Symptom relief Recruiting nowThis study tests two different nerve blocks to control pain after video-assisted lung surgery. One block targets a muscle plane, the other targets individual nerves. Researchers will measure pain levels, opioid use, and breathing problems in 80 adults aged 18-80. The goal is to f…
Sponsor: Kocaeli City Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
New eye drop battle: which offers better dry eye relief?
Symptom relief Recruiting nowThis study compares two preservative-free eye drops, Artelac Complete MDO and VISMED MULTI, for treating moderate to severe dry eye disease. About 160 adults who have used tear substitutes for at least a month will use one of the two drops for 90 days. Researchers will measure ch…
Phase: NA • Sponsor: Dr. Gerhard Mann chem.-pharm. Fabrik GmbH • Aim: Symptom relief
Last updated Jun 27, 2026 12:34 UTC
-
Cold plasma could heal stubborn wounds faster
Symptom relief Recruiting nowThis study tests whether a cold helium plasma device is safe and tolerable for people with chronic wounds, such as leg ulcers or pressure sores. About 40 adults with wounds that have not healed for over 4 weeks will receive the treatment. The goal is to see if cold plasma can red…
Phase: NA • Sponsor: Centre Hospitalier Régional d'Orléans • Aim: Symptom relief
Last updated Jun 27, 2026 12:34 UTC
-
Laser zaps burn scars: new hope for smoother skin?
Symptom relief Recruiting nowThis study tests whether a special laser can make burn scars look and feel better. Researchers will treat mature burn scars on the body and measure changes in scar height, texture, color, and flexibility. The study involves 6 adults in Winnipeg with scars that are 6-12 months old…
Phase: NA • Sponsor: University of Manitoba • Aim: Symptom relief
Last updated Jun 27, 2026 12:34 UTC
-
Can a psoriasis drug tame Immunotherapy's harsh side effects?
Symptom relief Recruiting nowThis pilot study tests whether brodalumab, a drug used for autoimmune conditions like psoriasis, can safely reduce immune-related side effects caused by cancer immunotherapy. About 11 adults with advanced solid tumors who developed these side effects will receive brodalumab injec…
Phase: PHASE1 • Sponsor: Brian Henick, MD • Aim: Symptom relief
Last updated Jun 27, 2026 12:33 UTC
-
Laser treatment may soften and flatten burn scars
Symptom relief Recruiting nowThis study looks at whether pulsed dye laser therapy can make burn scars less red, softer, flatter, and more flexible. Researchers will treat people with burn scars that are 1 to 6 months old and living in Winnipeg. The goal is to see if the laser helps scars heal better.
Phase: NA • Sponsor: University of Manitoba • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC
-
New shot may help heal tough scars
Symptom relief Recruiting nowThis study tests a new drug called 9MW3811 for people with thick, raised scars that haven't improved in 6 months. About 30 adults will receive either the drug or a placebo to see if it makes scars look and feel better. The goal is to reduce scar thickness, color, pain, and itchin…
Phase: PHASE2 • Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 12:30 UTC
-
Heat and hydrogen peroxide: a new hope for stubborn warts?
Symptom relief Recruiting nowThis study tests whether combining heat therapy (hyperthermia) with a common antiseptic (3% hydrogen peroxide) can clear stubborn viral warts that haven't responded to other treatments. About 80 adults with warts lasting two years or more will receive either the combination treat…
Phase: NA • Sponsor: First Hospital of China Medical University • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
Simple gel may prevent painful side effect of liver cancer drug
Symptom relief Recruiting nowThis study tests if applying a topical gel (indomethacin) to the hands before starting sorafenib can prevent or reduce hand-foot skin reactions, a common and painful side effect. About 39 adults with advanced liver cancer will use the gel twice daily for up to 12 weeks. The goal …
Phase: PHASE2 • Sponsor: National Taiwan University Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:28 UTC
-
New shot aims to stop the maddening itch of prurigo nodularis
Symptom relief Recruiting nowThis study tests an injection called SHR-1819 to see if it can safely reduce the intense itching caused by prurigo nodularis, a chronic skin condition with hard, itchy bumps. About 423 adults will receive either the drug or a placebo, and researchers will track how much their wor…
Phase: PHASE2, PHASE3 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 12:25 UTC
-
Can we spot cancer before it starts? a massive study aims to find out
Knowledge-focused Recruiting nowThis study is building a large collection of blood, saliva, urine, stool, and tissue samples from people who are at increased risk of cancer, including those with genetic predispositions, survivors of childhood or adult cancer, or those with precancerous conditions. The goal is t…
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Aug 18, 2026 03:00 UTC
-
Massive study aims to uncover cancer secrets in rare bone marrow diseases
Knowledge-focused Recruiting nowThis natural history study follows up to 4,000 people with inherited bone marrow failure syndromes (IBMFS) and their families to learn why they are prone to certain cancers. Researchers will track health over time, collect genetic samples, and look for clues that separate those w…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 03:00 UTC
-
Scientists launch major study to uncover secrets of insulin resistance
Knowledge-focused Recruiting nowThis study aims to learn more about insulin resistance and diabetes by collecting blood and skin samples from up to 1,200 participants, including patients with severe insulin resistance and their family members. Researchers will study genetics and how insulin works in the body to…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Aug 18, 2026 03:00 UTC
-
Scientists dig into skin bugs to unlock eczema secrets
Knowledge-focused Recruiting nowThis study looks at the tiny organisms living on our skin—like bacteria and fungi—and how they might differ in people with eczema (atopic dermatitis). Researchers will collect skin samples from healthy volunteers and patients aged 2 to 40 with moderate to severe eczema, as well a…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 03:00 UTC
-
New study aims to unlock secrets of rare cholesterol diseases
Knowledge-focused Recruiting nowThis natural history study is observing up to 250 people with Smith-Lemli-Opitz syndrome and related cholesterol disorders, as well as their relatives. Researchers will track symptoms, development, and lab results over several years to find better ways to measure disease progress…
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) • Aim: Knowledge-focused
Last updated Aug 18, 2026 03:00 UTC
-
New registry to track alopecia areata in teens
Knowledge-focused Recruiting nowThis registry will follow 1500 adolescents aged 12-17 with severe alopecia areata, a condition causing hair loss. Researchers will collect data from routine dermatology visits to better understand the disease's natural history, how it is managed, and what treatments are used. The…
Sponsor: CorEvitas • Aim: Knowledge-focused
Last updated Aug 18, 2026 03:00 UTC
-
Scientists seek clues to fungal infections in immune system study
Knowledge-focused Recruiting nowThis study aims to understand why some people are more prone to fungal infections, especially from Candida yeast. Researchers will collect blood, saliva, urine, and tissue samples from people with immune disorders, their family members, and healthy volunteers. No treatment is giv…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Aug 18, 2026 03:00 UTC
-
Researchers launch major study to unravel mysteries of muscle disease
Knowledge-focused Recruiting nowThis study aims to learn more about myositis, a group of diseases that cause muscle inflammation and damage. Researchers will observe up to 1,200 children and adults with myositis, along with healthy volunteers, to track changes in the immune system and other health problems over…
Sponsor: National Institute of Environmental Health Sciences (NIEHS) • Aim: Knowledge-focused
Last updated Aug 18, 2026 03:00 UTC
-
Could your genes raise your melanoma risk? new study seeks answers
Knowledge-focused Recruiting nowThis study aims to understand how genetics and environmental factors contribute to melanoma, a serious skin cancer. Researchers will enroll up to 3,000 people with a personal or family history of melanoma or related conditions. Participants will fill out questionnaires, provide b…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 03:00 UTC
-
Scientists seek samples to build better Cancer-Killing drugs
Knowledge-focused Recruiting nowThis study collects blood, urine, bone marrow, and tumor samples from people with hairy cell leukemia and other blood cancers, as well as from healthy volunteers. Researchers will use these samples to study the diseases and develop new treatments called immunotoxins, which use an…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 03:00 UTC
-
Scientists launch Long-Term study to unravel mysterious immune condition
Knowledge-focused Recruiting nowThis study follows 950 people with idiopathic CD4+ lymphocytopenia (ICL), a rare condition where low CD4+ white blood cells raise infection risk. Researchers will track participants for up to 10 years, collecting medical history, blood samples, and infection data. The goal is to …
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Aug 18, 2026 03:00 UTC
-
NIH launches major study to unlock secrets of rare bone diseases
Knowledge-focused Recruiting nowThis study aims to collect information and bone samples from up to 1,000 people with bone or mineral disorders, such as tumor-induced osteomalacia or familial tumoral calcinosis. Participants receive standard medical evaluations and may provide bone tissue from surgery or a biops…
Sponsor: National Institute of Dental and Craniofacial Research (NIDCR) • Aim: Knowledge-focused
Last updated Aug 18, 2026 03:00 UTC
-
AI aims to end Skin-Tone bias in dermatology
Knowledge-focused Recruiting nowThis study is testing whether artificial intelligence can accurately classify skin pigment, sun sensitivity (phototype), and sun damage from standard photos of the arm. Researchers will enroll 1,500 adults from diverse backgrounds, combining objective color measurements, expert a…
Sponsor: Region Skane • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Can skin biopsies unlock new treatments for scleroderma?
Knowledge-focused Recruiting nowThis study aims to understand the cellular and molecular mechanisms behind systemic sclerosis (SSc), a rare autoimmune disease that causes skin and organ fibrosis. Researchers will collect skin punch biopsies and blood samples from 500 participants, including those with SSc and h…
Sponsor: Relation Therapeutics • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Scientists launch major study to unravel rare genetic conditions
Knowledge-focused Recruiting nowThis study aims to learn more about RASopathies, a group of genetic conditions that can cause developmental issues, birth defects, and increased cancer risk. Researchers will follow up to 500 people of any age who have or may have a RASopathy, along with their family members, for…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
A tiny drop of blood might be enough: study tests fingerstick accuracy
Knowledge-focused Recruiting nowThis study collects blood samples from 10,000 healthy adults using both a fingerstick and a traditional needle draw from the arm. The goal is to compare lab results from the two methods and see how well fingerstick samples hold up after a few days of storage. The findings could h…
Sponsor: Roman Health Ventures Inc. • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Massive lung disease registry aims to unlock secrets of progressive fibrosis
Knowledge-focused Recruiting nowThis registry is following 3,000 adults with idiopathic pulmonary fibrosis (IPF) or other chronic fibrosing interstitial lung diseases (ILDs) to understand how these conditions progress over time. Researchers collect information on symptoms, treatments, quality of life, and store…
Sponsor: Duke University • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
New study screens for hidden genetic marker in mysterious mast cell disorders
Knowledge-focused Recruiting nowThis study aims to find how common the KIT D816V mutation is in people with suspected clonal mast cell disease. Researchers will collect blood samples from 450 participants and test them using two sensitive methods. The results may improve understanding and diagnosis of these rar…
Sponsor: Blueprint Medicines Corporation • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Scientists study leishmania infections to improve diagnosis and care
Knowledge-focused Recruiting nowThis study looks at how leishmaniasis infections progress and respond to treatment. It involves up to 289 people aged 3 to 100 with known or suspected leishmaniasis. Researchers will collect blood and tissue samples to learn more about the disease and test different treatments. T…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Scientists seek skin samples to unlock disease secrets
Knowledge-focused Recruiting nowThis study collects biological samples—like blood, skin biopsies, and swabs—from people with or at risk for skin diseases, as well as healthy volunteers. Researchers will use these samples to study the causes of skin conditions and explore potential treatments. Up to 700 particip…
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
Scientists launch major study to unravel mysterious metabolism disorders
Knowledge-focused Recruiting nowThis study aims to learn more about rare disorders that affect how the body processes chemicals called pyrimidines and purines. These disorders can cause problems in the brain, blood, kidneys, and immune system, ranging from mild to life-threatening. Researchers will compare test…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
PCOS study hunts for genetic clues behind severe insulin resistance
Knowledge-focused Recruiting nowThis study aims to find out whether some women diagnosed with polycystic ovary syndrome (PCOS) actually have a rare genetic condition causing severe insulin resistance. Researchers will compare 25 women with a known LMNA gene mutation (linked to lipodystrophy) to 50 women with cl…
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Can brain scans reveal the hidden toll of hidradenitis suppurativa?
Knowledge-focused Recruiting nowThis observational study uses brain imaging to explore whether people with hidradenitis suppurativa (HS) have differences in resting brain activity compared to healthy individuals. Researchers will also track how these brain patterns relate to disease severity, pain, sleep, mood,…
Sponsor: Second Xiangya Hospital of Central South University • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Could childhood trauma fuel skin inflammation?
Knowledge-focused Recruiting nowThis study investigates how inflammatory genes are regulated in people with hidradenitis suppurativa (HS), a chronic skin condition causing painful lumps. Researchers will compare inflammatory markers in HS patients versus healthy controls. An optional sub-study explores whether …
Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Scientists probe how eczema drugs alter skin microbes
Knowledge-focused Recruiting nowThis study examines how common eczema treatments, including antibiotics and bleach baths, change the types and amounts of bacteria on the skin. Researchers will compare people with eczema to healthy volunteers. The goal is to understand the skin microbiome better, not to test a n…
Phase: PHASE2 • Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Can a smartphone app keep cancer patients safer during treatment?
Knowledge-focused Recruiting nowThis study is testing whether a mobile app called Vigilant can help monitor side effects in 100 people with skin cancer or melanoma who are starting a specific type of immunotherapy. Participants will use the app to report any symptoms they experience, and researchers will track …
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Scientists launch deep dive into rare bleeding and lung disease
Knowledge-focused Recruiting nowThis study aims to learn more about Hermansky-Pudlak Syndrome (HPS), a rare inherited disease that causes light skin/eye color, bleeding problems, and often deadly lung scarring. Researchers will follow 600 people with HPS and their family members to track how the disease progres…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Scientists investigate rare breast cancer subtype to improve future care
Knowledge-focused Recruiting nowThis study looks back at medical records of 250 people with a rare type of breast cancer called apocrine lobular carcinoma. Researchers want to understand how this cancer behaves, what treatments patients received, and how they did over time. No new treatments are tested — the go…
Sponsor: Istituto Oncologico Veneto IRCCS • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Can mapping tumor DNA unlock personalized breast cancer care?
Knowledge-focused Recruiting nowThe AURORA study is collecting tumor and blood samples from 1,300 people with metastatic breast cancer across Europe. By analyzing genetic changes in both the original and metastatic tumors, researchers hope to understand why some patients respond well to therapy while others do …
Phase: NA • Sponsor: Jules Bordet Institute • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Eczema registry aims to map Real-World treatment journeys
Knowledge-focused Recruiting nowThis study is a registry that will follow 1,000 adults and teens with atopic dermatitis (eczema) who are starting or switching systemic treatments. Researchers will track which treatments people use, how long they take them, and why they change or stop. The goal is to better unde…
Sponsor: Sanofi • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Can Real-World data unlock better skin disease care?
Knowledge-focused Recruiting nowThis observational study aims to collect and analyze data from up to two million patients with dermatologic conditions like vitiligo, atopic dermatitis, alopecia areata, and hidradenitis suppurativa, as well as their healthcare providers. By reviewing treatment patterns, outcomes…
Sponsor: Target PharmaSolutions, Inc. • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
New device sucks up skin secrets to unlock baby eczema mysteries
Knowledge-focused Recruiting nowThis study will test a new, gentle device that collects fluid from the skin of babies up to 6 months old. Researchers want to see if it's comfortable and can measure chemical signals that may explain why some babies get eczema. By comparing healthy babies and those with eczema, t…
Sponsor: King's College London • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
Scientists hunt for gene behind rare kidney cancer syndrome
Knowledge-focused Recruiting nowThis study aims to uncover the genetic causes of hereditary leiomyomatosis renal cell cancer (HLRCC), a condition that can lead to painful skin bumps, uterine fibroids, and kidney tumors. Researchers will study people with known or suspected HLRCC and their family members to iden…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
Rare disease mystery: can tracking SPLIS patients unlock its secrets?
Knowledge-focused Recruiting nowThis study follows people with SPLIS, a rare inherited metabolic condition, to map its natural history—how the disease unfolds over time. Researchers will track growth, organ function, quality of life, and survival in about 28 participants. The goal is to understand the full rang…
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
Eczema patients needed for study on improving treatment habits
Knowledge-focused Recruiting nowThis study aims to understand why many people with atopic dermatitis (eczema) don't use their topical medication as prescribed, which can lead to worse symptoms and higher healthcare costs. About 30 adults and children with active dermatitis will be divided into groups to receive…
Phase: NA • Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
Scientists dig into skin healing mysteries in immune disorders
Knowledge-focused Recruiting nowThis study aims to understand how the immune system and skin healing are connected in people with primary immunodeficiency, psoriasis, or eczema, as well as in healthy volunteers. Researchers will collect skin biopsies, blood samples, and optional skin swabs to analyze microbes a…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
New anesthetic may spare the diaphragm during arm surgery
Knowledge-focused Recruiting nowThis study compares two types of numbing medicine for upper limb surgery: a standard one and a longer-acting version. Researchers want to see how quickly the diaphragm (the main breathing muscle) recovers after the nerve block. 120 adults having arm or hand surgery will be split …
Phase: NA • Sponsor: Zhejiang University • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC
-
Dietary change explored as cancer support strategy
Knowledge-focused Recruiting nowThis early-stage study tests whether people with advanced solid tumors can safely follow a diet low in methionine, an amino acid found in many proteins. Researchers will measure how well participants stick to the diet, check for side effects, and track changes in blood methionine…
Phase: EARLY_PHASE1 • Sponsor: University of California, Irvine • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
Tiny nail vessels may reveal clues about psoriasis severity
Knowledge-focused Recruiting nowThis observational study examines nailfold capillaries — tiny blood vessels at the base of the fingernails — in people with psoriasis. Researchers will use a special microscope to see if these vessels look different depending on how severe the psoriasis is. The goal is to find a …
Sponsor: Al-Azhar University • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
Blood test may reveal hidden clues to hair loss severity
Knowledge-focused Recruiting nowThis study investigates whether two substances in the blood—GPX4 and MDA—are linked to the severity of alopecia areata, a condition that causes patchy hair loss. Researchers will compare levels of these markers in 104 people with alopecia areata and 52 healthy volunteers. The goa…
Sponsor: Istanbul Training and Research Hospital • Aim: Knowledge-focused
Last updated Aug 01, 2026 00:00 UTC
-
Can ultrasound reveal why lipedema makes walking hard?
Knowledge-focused Recruiting nowThis study investigates how lipedema — a condition causing abnormal fat buildup in the legs — affects muscle structure and walking. Researchers will use ultrasound to measure leg muscle and tendon thickness in 45 women with lipedema and compare them to 45 healthy women. A foot-pr…
Sponsor: Marmara University • Aim: Knowledge-focused
Last updated Jul 26, 2026 00:00 UTC
-
Can a new questionnaire better measure lipedema symptoms in turkish women?
Knowledge-focused Recruiting nowLipedema is a chronic condition causing painful fat buildup in the legs, mostly in women. This study is testing whether a Turkish translation of the Rapprich Lipedema Symptomatic Assessment Questionnaire is a reliable and valid tool for measuring symptom severity. Researchers wil…
Sponsor: Marmara University • Aim: Knowledge-focused
Last updated Jul 26, 2026 00:00 UTC
-
Which finger or earlobe? a study tests the best spot for oxygen monitoring in lung disease
Knowledge-focused Recruiting nowThis study compares oxygen readings taken from the finger and the earlobe during a six-minute walk test in people with interstitial lung disease. The goal is to see if one location gives more accurate measurements of oxygen levels during exercise. The results could help doctors d…
Sponsor: Hospital de Granollers • Aim: Knowledge-focused
Last updated Jul 25, 2026 00:00 UTC
-
Can a genetic hunt solve the mystery of a painful skin condition?
Knowledge-focused Recruiting nowLichen sclerosus is a chronic skin condition that causes itching, pain, and scarring, often in the genital area, and raises the risk of skin cancer. This study aims to identify genetic variants linked to the disease by analyzing DNA from families that have multiple members with l…
Sponsor: Gudula Kirtschig • Aim: Knowledge-focused
Last updated Jul 24, 2026 00:00 UTC
-
Night shift workers' skin may struggle to fix sun damage, study suggests
Knowledge-focused Recruiting nowThis pilot study investigates whether working night shifts changes how the skin repairs DNA damage caused by ultraviolet B (UVB) radiation, a type of artificial sunlight. Researchers will take small skin samples from 48 fair-skinned day and night shift workers at two times of day…
Phase: NA • Sponsor: Wright State University • Aim: Knowledge-focused
Last updated Jul 19, 2026 00:00 UTC
-
Skin sodium levels may hold clues to eczema in older adults
Knowledge-focused Recruiting nowThis observational study investigates factors linked to sodium stored in the skin of healthy adults and people with atopic dermatitis (eczema) aged 50 and older. Researchers aim to see if diet and skin barrier function affect skin sodium levels, and whether those levels are tied …
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jul 16, 2026 00:00 UTC
-
Skin microbes may hold key to eczema and psoriasis Flare-Ups
Knowledge-focused Recruiting nowThis study tracks how bacteria living on the skin change over time in people with eczema (atopic dermatitis), psoriasis, and healthy skin. Researchers collect skin swabs, tape strips, and blood samples to measure levels of Staphylococcus aureus and other microbes. The goal is to …
Sponsor: University of Rochester • Aim: Knowledge-focused
Last updated Jul 16, 2026 00:00 UTC
-
Hidden heart risk: routine cancer scans could reveal cardiovascular danger in breast cancer survivors
Knowledge-focused Recruiting nowThis study tests whether measuring calcium buildup in heart arteries from routine radiotherapy planning CT scans can identify breast cancer patients at risk for heart disease. Researchers will share this personalized risk information with patients and their doctors to see if it i…
Phase: NA • Sponsor: UMC Utrecht • Aim: Knowledge-focused
Last updated Jul 16, 2026 00:00 UTC
-
Hidden vein issues may worsen lipedema pain, new study hints
Knowledge-focused Recruiting nowThis study looks at whether vein problems are linked to pain, swelling, and daily function in women with lipedema. Researchers will use ultrasound to check leg veins and ask participants about their symptoms. The goal is to better understand how these conditions interact, which c…
Sponsor: Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey • Aim: Knowledge-focused
Last updated Jul 16, 2026 00:00 UTC
-
Blood pressure may predict bedsores in intensive care
Knowledge-focused Recruiting nowThis study investigates whether blood pressure levels influence the development of bedsores (pressure ulcers) in adult patients confined to bed in an internal medicine intensive care unit. Researchers will monitor blood pressure and other vital signs daily, and assess skin condit…
Sponsor: Yuzuncu Yil University • Aim: Knowledge-focused
Last updated Jul 15, 2026 00:00 UTC
-
Could active sitting make you sharper and burn more calories?
Knowledge-focused Recruiting nowThis study looks at how four different ways of sitting—from a regular chair to an exercise chair used actively—affect your muscles, seated pressure, thinking speed, and calorie burn. Healthy adults aged 18 to 70 will try each sitting position while researchers measure muscle acti…
Phase: NA • Sponsor: University of Miami • Aim: Knowledge-focused
Last updated Jul 15, 2026 00:00 UTC
-
New drug BW-41012 enters first human safety tests
Knowledge-focused Recruiting nowThis early-phase trial will test the safety and tolerability of a single injection of BW-41012 in 40 healthy adults aged 18 to 65. Participants will be randomly assigned to receive either the drug or a placebo, and researchers will monitor for side effects and measure how the dru…
Phase: PHASE1 • Sponsor: Shanghai Argo Biopharmaceutical Co., Ltd. • Aim: Knowledge-focused
Last updated Jul 11, 2026 00:00 UTC
-
Fat tissue disorder may worsen knee arthritis, new study hints
Knowledge-focused Recruiting nowThis study will compare women with knee osteoarthritis who also have lipedema (a fat tissue disorder) to those without lipedema. Researchers will use ultrasound to measure knee cartilage thickness and questionnaires to assess pain and daily function. The goal is to understand if …
Sponsor: Izmir Democracy University • Aim: Knowledge-focused
Last updated Jul 11, 2026 00:00 UTC
-
Scientists probe keloid tissue for clues to stop overgrown scars
Knowledge-focused Recruiting nowThis study looks at keloid scars—raised, overgrown scars that can be itchy or painful—to understand why they form. Researchers will compare keloid tissue with normal skin from the same person, using lab tests to spot key molecules that drive scar growth. The goal is to uncover ne…
Sponsor: The Fourth Affiliated Hospital of Zhejiang University School of Medicine • Aim: Knowledge-focused
Last updated Jul 08, 2026 00:00 UTC
-
Could starting immunotherapy earlier improve outcomes for High-Risk melanoma?
Knowledge-focused Recruiting nowThis study observes patients with high-risk stage II melanoma to see if starting anti-PD-1 immunotherapy before surgery leads to better outcomes compared to the usual timing after surgery. Researchers will track when patients begin systemic therapy and compare results between the…
Sponsor: AC Camargo Cancer Center • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Scientists probe kidney cell metabolism to unlock secrets of ANCA vasculitis
Knowledge-focused Recruiting nowThis study investigates how changes in kidney cell metabolism relate to the rate of kidney function decline in people with ANCA vasculitis and other kidney diseases. Researchers will analyze kidney biopsy samples and blood/urine tests from 146 participants over one year. The goal…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
AI reads skin lesions to predict cancer aggressiveness
Knowledge-focused Recruiting nowThis study tests whether an artificial intelligence (AI) model can accurately classify basal cell carcinoma (a common skin cancer) as low-risk or high-risk using dermoscopic images. Researchers will also see if the AI can predict specific subtypes of the cancer. The model's perfo…
Sponsor: Istanbul Training and Research Hospital • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Can a simple blood test predict leukemia risk after cancer therapy?
Knowledge-focused Recruiting nowThis study investigates clonal hematopoiesis (CH) — small mutations in blood cells that can arise naturally or after cancer treatment — in adults receiving chemotherapy or radiation for solid tumors like breast, lung, or colorectal cancer. Researchers will collect blood, saliva, …
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Skin clues could unmask rare nerve disease in kids
Knowledge-focused Recruiting nowThis study looks at children under 15 with neurofibromatosis type 2 (NF2), a rare genetic condition that causes nerve tumors. Researchers want to see if skin and mouth lesions can help diagnose NF2 earlier than current methods, which rely on hearing, nerve, and eye symptoms. By e…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
COVID-19's skin secrets: could chilblains hold clues to the virus?
Knowledge-focused Recruiting nowThis study looks at skin problems that appear during a COVID-19 infection, with a special focus on chilblains (painful red or purple bumps on fingers or toes). Researchers want to understand why these skin changes happen—whether from the virus itself, tiny blood clots, or inflamm…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
New registry aims to unlock secrets of cancer in older adults
Knowledge-focused Recruiting nowThis research study creates a registry of older adults with cancer to collect information about their health, treatments, and outcomes. Participants complete a geriatric assessment and allow researchers to follow their medical records. The goal is to better understand how cancer …
Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
New study aims to unlock secrets of systemic sclerosis through patient samples
Knowledge-focused Recruiting nowThis study is gathering blood, stool, and skin samples from 100 adults with systemic sclerosis to learn more about the disease. Researchers will also track health information like skin thickness, lung function, and quality of life over time. The goal is to build a biobank for fut…
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Worldwide eczema study aims to uncover disparities in care
Knowledge-focused Recruiting nowThis international study observes how people with atopic dermatitis (eczema) access healthcare, what treatments they receive, and how the disease affects their daily lives. Researchers will collect data from routine medical records of about 9,600 participants across multiple coun…
Sponsor: Julia Tatjana Maul • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Worldwide study aims to uncover hidden patterns in hidradenitis suppurativa care
Knowledge-focused Recruiting nowThis international study observes how people with hidradenitis suppurativa (a chronic skin condition) access healthcare, what treatments they receive, and how the disease affects their quality of life. Researchers collect data from routine medical records across multiple countrie…
Sponsor: Julia Tatjana Maul • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Blood test aims to spot hidden cancer cells in 9 tumor types
Knowledge-focused Recruiting nowThis study is looking for certain cells in the blood of people with 9 types of advanced cancers that have spread. Researchers will take one blood sample from each of 450 participants before they start a new treatment. They will use two different lab methods to see if they can fin…
Phase: NA • Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Scientists map hair loss at the cellular level to unlock new treatments
Knowledge-focused Recruiting nowThis study aims to understand why hair follicles stop working in male pattern baldness. Researchers will collect scalp samples from 12 men (younger and older) with and without hair loss. Using advanced technology, they will map cells and genes to find key targets for future treat…
Sponsor: The First Affiliated Hospital of Xinxiang Medical College • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
2500 psoriasis patients enrolled to see how new treatments work in real life
Knowledge-focused Recruiting nowThis study follows 2500 adults with moderate-to-severe plaque psoriasis who are starting a new advanced therapy. Researchers will check their progress at 16 and 24 weeks using questionnaires. The goal is to build a detailed picture of early treatment responses in real-world setti…
Sponsor: CorEvitas • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Can a skin biopsy tell your doctor which treatment will work?
Knowledge-focused Recruiting nowThis study is collecting skin and blood samples from 830 people with chronic inflammatory skin diseases like psoriasis, eczema, and lupus. Researchers want to find biological markers that can predict how well a person will respond to treatment after one year. The goal is to move …
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:08 UTC
-
Could your diet lower breast cancer risk? new study investigates
Knowledge-focused Recruiting nowThis study follows 960 women at high risk for breast cancer to see if their diet's inflammatory potential is linked to cancer risk. Participants complete questionnaires and physical exams over time. The goal is to identify modifiable risk factors to improve prevention and early d…
Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Eczema flare predictor device tested in new study
Knowledge-focused Recruiting nowThis study is testing a handheld device called Nevisense Go to see if it can predict eczema (atopic dermatitis) flares before they become visible or cause symptoms. About 450 people aged 12 to 89 with a history of eczema flares will use the device at home for 90 days. The goal is…
Sponsor: Castle Biosciences Incorporated • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Eczema breakthrough? DNA in blood could predict Flare-Ups
Knowledge-focused Recruiting nowThis study looks at whether tiny DNA fragments released from damaged skin cells into the blood can help measure eczema severity. Researchers will compare blood and skin samples from 80 adults with eczema and healthy volunteers. The goal is to understand how these DNA fragments tr…
Sponsor: Zhongda Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Scientists hunt for bacterial clues in vitiligo patients
Knowledge-focused Recruiting nowThis study looks at the bacteria living on the skin and in the gut of 100 adults with and without vitiligo. Researchers want to see if people with active or stable vitiligo have different bacteria compared to healthy volunteers. No treatments or drugs are given—just samples colle…
Sponsor: Northwestern University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Massive eye gene bank aims to unlock secrets of rare blindness
Knowledge-focused Recruiting nowThis study aims to collect DNA samples and detailed eye exam data from 1,000 people with rare inherited eye diseases like aniridia, Best disease, and albinism. Participants provide a saliva or blood sample and share their eye health records. The goal is to expand a research repos…
Sponsor: National Eye Institute (NEI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Lupus Patients' shingles vaccine response under the microscope
Knowledge-focused Recruiting nowThis study looks at how well the shingles vaccine (Shingrix) works in people with lupus compared to healthy people of the same age and sex. Researchers will measure immune cell responses after two doses and follow participants for up to 5 years. The goal is to understand if the v…
Sponsor: Seoul National University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
World's largest psoriasis care study launches to uncover treatment gaps
Knowledge-focused Recruiting nowThis study observes how people with psoriasis receive care in different countries. Researchers will collect data from routine doctor visits to understand treatment patterns, disease severity, and quality of life. The goal is to identify gaps in healthcare delivery and improve out…
Sponsor: Julia Tatjana Maul • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Could a simple hand soak reveal cystic fibrosis risk?
Knowledge-focused Recruiting nowThis study looks at whether soaking hands in water for up to 20 minutes can be a simple screening tool for cystic fibrosis (CF) carrier status. Researchers will take photos of participants' hands and score the wrinkling, both by human observation and using a computer algorithm. T…
Sponsor: University of Iowa • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
No travel needed: new study uses video calls to uncover genetic secrets of childhood muscle disease
Knowledge-focused Recruiting nowThis study aims to learn why myotonic dystrophy type 1 affects children differently than adults, and why symptoms vary even within the same family. Researchers will observe 100 children (ages 0-17) through video calls and simple at-home activities, and analyze their genes from a …
Sponsor: University of Rochester • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
Tiny study aims to unlock why dupilumab works for eczema
Knowledge-focused Recruiting nowThis study looks at how dupilumab, an approved eczema drug, changes immune cells in the skin. Researchers will take skin samples from 15 adults with moderate-to-severe eczema before and after treatment. The goal is to understand the molecular changes that lead to improvement, not…
Phase: PHASE4 • Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
5,000 patients to help unlock secrets of inflammatory heart disease
Knowledge-focused Recruiting nowThis study aims to learn how well heart scans (MRI, ultrasound, PET) can detect and predict outcomes in people with suspected or known inflammatory heart diseases. Researchers will follow 5,000 adults for one year to see how often heart involvement is confirmed and how it affects…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
Scientists dig into why diabetic wounds stay open
Knowledge-focused Recruiting nowThis study looks at why wounds heal slowly or not at all in people with diabetes. Researchers will collect blood and wound fluid from 250 adults with chronic wounds to compare immune cells between diabetic and non-diabetic participants. The goal is to understand the biological re…
Sponsor: University of Pittsburgh • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
Melanoma metabolism under the microscope: can energy use predict spread?
Knowledge-focused Recruiting nowThis study looks at how melanoma tumors process energy, specifically glucose, to see if certain metabolic patterns are linked to cancer spread. Researchers will give a special glucose tracer to 400 adults with melanoma before their surgery and analyze the tumor tissue. Participan…
Sponsor: University of Texas Southwestern Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
New drug PG-033 enters first human safety tests
Knowledge-focused Recruiting nowThis early-stage study tests the safety of a new drug called PG-033 in 52 healthy adults aged 18 to 45. Participants receive either a single dose of PG-033 or a placebo, and researchers monitor side effects and how the drug moves through the body. The study also checks if a high-…
Phase: PHASE1 • Sponsor: Prime Gene Therapeutics Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
New study monitors how fast psoriasis drugs work in daily life
Knowledge-focused Recruiting nowThis study follows 2,500 adults with moderate-to-severe plaque psoriasis who are starting a new advanced therapy. Researchers will collect data at the start and after 2, 4, and 16 weeks to see how quickly the treatment works. The goal is to build a detailed picture of early treat…
Sponsor: CorEvitas • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Scientists dig into immune signals to unlock psoriasis mystery
Knowledge-focused Recruiting nowThis study looks at 40 adults with psoriasis—some with joint pain (psoriatic arthritis) and some without—to compare immune signals in their blood and skin. Researchers want to understand why some people develop joint problems. Participants give blood and skin samples for lab anal…
Phase: NA • Sponsor: Poitiers University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
French study tracks Real-World skin cancer care for 1500 patients
Knowledge-focused Recruiting nowThis study follows 1,500 French patients with advanced cutaneous squamous cell carcinoma (a type of skin cancer) who need systemic treatment (medication that works throughout the body). Researchers will collect information from medical records and ongoing visits to see how treatm…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
New database aims to crack the code on three rare skin cancers
Knowledge-focused Recruiting nowThis study is building a large French database of patients with three rare skin cancers: Merkel cell carcinoma, advanced basal cell carcinoma, and cutaneous adnexal carcinomas. Researchers will track up to 9,000 participants to learn how these cancers behave, what factors affect …
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Laser wounds may hold key to skin cancer shield
Knowledge-focused Recruiting nowThis study looks at how a laser that makes tiny holes in the skin might help protect against skin cancer. Researchers want to find out where certain skin cells come from after this laser treatment. They are recruiting 12 adults who are already scheduled for tummy tuck surgery to …
Phase: NA • Sponsor: Wright State University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
AI reads your symptom stories to find hidden medical clues
Knowledge-focused Recruiting nowThis study collects anonymous symptom descriptions from 1,000 adults through an online platform. An AI tool then searches medical literature to see if it can find reliable biological signals in the free-text descriptions. The goal is to test how accurate and consistent the AI's f…
Sponsor: OpenGenome • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
Massive T-Cell lymphoma database aims to unlock new insights
Knowledge-focused Recruiting nowThis study is creating a large database of information and tissue samples from 1,000 people with T-cell lymphoma. Researchers will use this data to learn more about the disease and how to improve patient outcomes. Participants provide medical information and optional blood and na…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
Gene clue to worse eczema uncovered in new study
Knowledge-focused Recruiting nowThis study looks at whether a specific genetic change (IL-4Ra R576) is linked to more severe eczema. Researchers will measure skin symptoms, immune markers, and skin bacteria in 111 people aged 6 to 65 with atopic dermatitis. No new treatment is being tested; the goal is to bette…
Sponsor: Boston Children's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
Female athlete study: hormones may change strength and hydration
Knowledge-focused Recruiting nowThis study looks at how natural menstrual cycles and birth control pills affect strength, hydration, and energy balance in 40 female athletes. Researchers will measure muscle strength, body water, and energy use at different times of the month. The goal is to better understand ho…
Sponsor: Faculdade de Motricidade Humana • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Blood tests could predict melanoma treatment success
Knowledge-focused Recruiting nowThis study enrolls 200 people with acral or cutaneous melanoma who are starting standard immunotherapy. Researchers will collect blood samples every 3 weeks and tumor tissue after about 3 months of treatment. By analyzing circulating tumor cells, DNA, and other markers, they aim …
Sponsor: Xijing Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Could weak legs be making it hard to breathe? new study investigates
Knowledge-focused Recruiting nowThis study looks at why people with interstitial lung disease (ILD) often feel breathless and have trouble exercising. Researchers think leg muscle problems might be a cause. They will measure leg muscle strength and structure in 40 ILD patients and test how extra oxygen affects …
Phase: NA • Sponsor: University of British Columbia • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
300 patients tracked to uncover hidden cancer risks in common mouth condition
Knowledge-focused Recruiting nowThis study follows 300 people with oral lichen planus (a chronic mouth condition) for at least 6 months to see how often it turns into oral cancer. Researchers will also look for patterns and risk factors that might predict this change. No new treatments are tested—the goal is si…
Sponsor: Catholic University of the Sacred Heart • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Scientists probe hidden clot risks in autoimmune skin disorders
Knowledge-focused Recruiting nowThis study looks at blood clotting in people with autoimmune skin diseases like bullous pemphigoid and lupus. Researchers will collect blood samples from 39 participants—some with active disease and some with mild or controlled disease—plus 15 healthy controls. They will measure …
Sponsor: University of Nebraska • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
Thai researchers hunt for genes behind rare sun allergy
Knowledge-focused Recruiting nowThis study looks at the genes of 47 Thai people with actinic prurigo, a rare skin condition triggered by sunlight. Researchers will compare their DNA to healthy volunteers to find genetic links. The goal is to understand why some people get this disease and why treatments work di…
Sponsor: Chulalongkorn University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
Can a virtual health coach get more minorities into cancer trials?
Knowledge-focused Recruiting nowThis study is testing whether a website with a virtual community health educator can help Black and Hispanic cancer patients in Florida learn about and sign up for clinical trials. About 350 adults will be randomly assigned to either a standard information portal or one with a vi…
Sponsor: University of Florida • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
New study aims to unlock mysteries of rare sun allergy disorders
Knowledge-focused Recruiting nowThis observational study is gathering information on how erythropoietic protoporphyria (EPP) and X-linked porphyria (XLP) affect people aged 12 and older. Over 6 months, researchers will track symptoms, light exposure, and blood levels of protoporphyrin IX (PPIX) in 50 participan…
Sponsor: Portal Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
100,000 volunteers needed to unlock secrets of chronic diseases
Knowledge-focused Recruiting nowThis study is collecting health information, lifestyle data, and biological samples from up to 100,000 adults to help researchers better understand diseases like lupus, celiac disease, and kidney disease. Participants provide data and samples through a direct-to-patient platform.…
Sponsor: Joined Bio • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
New skin scanner could reveal hidden changes in eczema treatment
Knowledge-focused Recruiting nowThis study tests whether a special microscope (reflectance confocal microscopy) can detect skin changes in people with moderate-to-severe eczema who are taking tralokinumab. The drug blocks a protein involved in inflammation and is already known to help eczema. Researchers want t…
Sponsor: Hôpitaux Drôme Nord • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Massive biobank launches to unlock secrets of chronic inflammation
Knowledge-focused Recruiting nowThis study is building a large database and biobank from 2200 people with chronic inflammatory diseases like lupus, multiple sclerosis, severe asthma, and psoriasis. Researchers will collect blood samples and track disease activity over time using standard medical scores. The goa…
Phase: NA • Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
AI spots hidden lumps that mess with insulin
Knowledge-focused Recruiting nowThis study tests whether a machine learning program can detect lipohypertrophy—hidden lumps under the skin caused by insulin injections—using portable ultrasound. About 100 people with diabetes will first have their injection sites scanned. In a second phase, 40 people found to h…
Phase: NA • Sponsor: University of British Columbia • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Researchers track Real-World treatment of serious ENT infections
Knowledge-focused Recruiting nowThis study is observing how doctors manage complicated infections of the ears, nose, throat, and neck in both children and adults. Researchers will track standard treatments like surgery or medication to understand current practices. No new treatments are being tested; the goal i…
Sponsor: University Medical Centre Ljubljana • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
Scientists hunt for eye disease clues in your tears
Knowledge-focused Recruiting nowThis study collects tear samples from 300 people with dry eye, infectious keratoconjunctivitis, mucous membrane pemphigoid, or allergic conjunctivitis. Researchers will analyze the proteins and metabolites in tears to create a unique fingerprint for each condition. The goal is to…
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
Stanford launches study to better understand rare blistering skin disease
Knowledge-focused Recruiting nowThis study is screening people with recessive dystrophic epidermolysis bullosa (RDEB), a rare genetic disease that causes painful blisters and open wounds from minor skin contact. Researchers at Stanford want to learn more about the disease and the patients' cells to develop new …
Sponsor: Stanford University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC